<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Killer-cell immunoglobulin-like receptor</title><meta name="description" content="Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of natural killer (NK) cells and a minority of T cells.[1][2] In humans, they are encoded in the leukocyte receptor complex (LRC) on chromosome 19q13.4; the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.[3][4] NK cells use KIRs to detect perturbations or absence of self-HLA class..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="KIR"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Killer-cell_immunoglobulin-like_receptor"/><meta property="og:title" content="Killer-cell immunoglobulin-like receptor"/><meta property="og:description" content="Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of natural killer (NK) cells and a minority of T cells.[1][2] In humans, they are encoded in the leukocyte receptor complex (LRC) on chromosome 19q13.4; the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.[3][4] NK cells use KIRs to detect perturbations or absence of self-HLA class..."/><meta property="og:url" content="https://grokipedia.com/page/Killer-cell_immunoglobulin-like_receptor"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Killer-cell immunoglobulin-like receptor"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:46.123Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Killer-cell immunoglobulin-like receptor"/><meta name="twitter:description" content="Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of natural killer (NK) cells and a minority of T cells.[1][2] In humans, they are encoded in the leukocyte receptor complex (LRC) on chromosome 19q13.4; the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.[3][4] NK cells use KIRs to detect perturbations or absence of self-HLA class..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="2bc5f4f7a4e9e42910aa893f3e75c114-3e6788ff6b6d1b70-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=2bc5f4f7a4e9e42910aa893f3e75c114,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.8000353435350187,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#killer-cell-immunoglobulin-like-receptor" class="transition-opacity hover:opacity-100 opacity-50">Killer-cell immunoglobulin-like receptor</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#killer-cell-immunoglobulin-like-receptors-function" class="transition-opacity hover:opacity-100 opacity-50">Killer-cell Immunoglobulin-like Receptors: Function</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#function" class="transition-opacity hover:opacity-100 opacity-50">Function</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#role-in-natural-killer-cells" class="transition-opacity hover:opacity-100 opacity-50">Role in natural killer cells</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#role-in-t-cells" class="transition-opacity hover:opacity-100 opacity-50">Role in T cells</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#nomenclature-and-classification" class="transition-opacity hover:opacity-100 opacity-50">Nomenclature and classification</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#receptor-types" class="transition-opacity hover:opacity-100 opacity-50">Receptor types</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#inhibitory-receptors" class="transition-opacity hover:opacity-100 opacity-50">Inhibitory receptors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#activating-receptors" class="transition-opacity hover:opacity-100 opacity-50">Activating receptors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#expression" class="transition-opacity hover:opacity-100 opacity-50">Expression</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#killer-cell-immunoglobulin-like-receptor-structure" class="transition-opacity hover:opacity-100 opacity-50">Killer-cell Immunoglobulin-like Receptor Structure</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#structure" class="transition-opacity hover:opacity-100 opacity-50">Structure</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#gene-structure" class="transition-opacity hover:opacity-100 opacity-50">Gene structure</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#genes" class="transition-opacity hover:opacity-100 opacity-50">Genes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#protein-structure" class="transition-opacity hover:opacity-100 opacity-50">Protein structure</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diversity" class="transition-opacity hover:opacity-100 opacity-50">Diversity</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#allelic-diversity" class="transition-opacity hover:opacity-100 opacity-50">Allelic diversity</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#genotype-and-haplotype-diversity" class="transition-opacity hover:opacity-100 opacity-50">Genotype and haplotype diversity</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#role-in-disease" class="transition-opacity hover:opacity-100 opacity-50">Role in disease</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#as-a-drug-target" class="transition-opacity hover:opacity-100 opacity-50">As a drug target</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#use-of-kirs-in-car-t-cell-therapy" class="transition-opacity hover:opacity-100 opacity-50">Use of KIRs in CAR T Cell Therapy</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="killer-cell-immunoglobulin-like-receptor" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Killer-cell immunoglobulin-like receptor<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>

















<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Killer-cell immunoglobulin-like receptors</strong> (<strong>KIRs</strong>), are a family of type I <span class="inline text-[1em] leading-7">transmembrane</span> <span class="inline text-[1em] leading-7">glycoproteins</span> expressed on the <span class="inline text-[1em] leading-7">plasma membrane</span> of <span class="inline text-[1em] leading-7">natural killer (NK)</span> cells and a minority of <span class="inline text-[1em] leading-7">T cells</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> In humans, they are encoded in the <span class="inline text-[1em] leading-7">leukocyte receptor complex</span> (LRC) on chromosome 19q13.4; the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> NK cells use KIRs to detect perturbations or absence of self-HLA class I molecules on infected, transformed, or allogeneic cells, including in reproductive contexts such as pregnancy. The KIR receptors were originally defined serologically by the Moretta groups in the early 1990s.</span>
<span class="mb-4 block break-words text-[1em] leading-7">They regulate the killing function of these cells by interacting with <span class="inline text-[1em] leading-7">major histocompatibility (MHC) class I</span> molecules, which are expressed on all nucleated cell types. KIR receptors can distinguish between MHC I allelic variants, which allows them to detect <span class="inline text-[1em] leading-7">virally</span> infected cells or <span class="inline text-[1em] leading-7">transformed cells</span>. KIRs are <span class="inline text-[1em] leading-7">paired receptors</span>, meaning some have activating and others have inhibitory functions; most KIRs are inhibitory: their recognition of MHC molecules suppresses the <span class="inline text-[1em] leading-7">cytotoxic</span> activity of their NK cell.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> The receptors collaborate to monitor and respond to the changes in HLA class I antigen on cells of the body.</span>
<span class="mb-4 block break-words text-[1em] leading-7">A limited number of KIRs are activating: their recognition of MHC molecules activates the cytotoxic activity of their cell.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_22abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Initial expression of KIRs on NK cells is <span class="inline text-[1em] leading-7">stochastic</span>, but NK cells undergo an educational process as they mature that alters the KIR expression to maximize the balance between effective defense and self-tolerance. KIR&#x27;s role in killing unhealthy self-cells and not killing healthy self-cells, involves them in protection against and propensity to viral infections such as HIV, HCV, autoimmune disease, and cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_72abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> KIR molecules are <span class="inline text-[1em] leading-7">polymorphic</span>: their <span class="inline text-[1em] leading-7">gene</span> sequences differ greatly across individuals. They are also <span class="inline text-[1em] leading-7">polygenic</span> so that it is rare for two unrelated individuals to possess the same KIR genotype.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Below is a list of the 16 KIR genes:</span>































































































<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7">Unlike T lymphocytes, resting NK cells use preformed lytic granules to kill target cells, implying a rapid cytolytic effect that requires a finely regulated control mechanism. The ability to spare normal tissues, but not transformed cells, is termed the &quot;<span class="inline text-[1em] leading-7">missing self</span>&quot; hypothesis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> This phenomenon is determined by MHC class Iâ€“specific inhibitory receptors that functionally dominate the triggering potentials induced by activating receptors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_73abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> Thus, NK cells use a complex array of inhibitory or activating receptor/ligand interactions, the balance of which regulates NK cell function and cytolytic activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> Receptors displaying this function evolved during phylogenesis following the rapid evolution of genes coding for MHC class I molecules. Thus, in primates and a few other species, evolved MHC class Iâ€“inhibitory receptors belong to the KIR immunoglobulin superfamily,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> while in rodents and other species the same function is under the control of type II integral transmembrane glycoproteins, structurally characterized as disulfide-linked homodimers belonging to the <span class="inline text-[1em] leading-7">Ly49</span> protein family.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> The factors controlling and regulating KIR expression on NK cells are not well understood. It is accepted that tolerance is a major driving force. Tolerance is a fundamental feature of the immune system and is required to prevent a system designed for attack from damaging itself.</span>
<h1 id="killer-cell-immunoglobulin-like-receptors-function" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Killer-cell Immunoglobulin-like Receptors: Function<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="function" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Function<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="role-in-natural-killer-cells" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Role in natural killer cells<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Natural killer (NK) cells</span> are a type of <span class="inline text-[1em] leading-7">lymphocyte</span> cell involved in the <span class="inline text-[1em] leading-7">innate immune system&#x27;s</span> response to viral infection and tumor transformation of host cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Like T cells, NK cells have many qualities characteristic of the <span class="inline text-[1em] leading-7">adaptive immune system</span>, including the production of â€œmemoryâ€ cells that persist following encounter with <span class="inline text-[1em] leading-7">antigens</span> and the ability to create a secondary recall response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Unlike T cells, NK cell receptors are <span class="inline text-[1em] leading-7">germline</span> encoded, and therefore do not require <span class="inline text-[1em] leading-7">somatic</span> gene rearrangements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Because NK cells target self cells, they have an intricate mechanism by which they differentiate self and non-self cells in order to minimize the destruction of healthy cells and maximize the destruction of unhealthy cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Natural killer cell <span class="inline text-[1em] leading-7">cytolysis</span> of target cells and <span class="inline text-[1em] leading-7">cytokine</span> production is controlled by a balance of inhibitory and activating signals, which are facilitated by NK cell receptors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> NK cell inhibitory receptors are part of either the immunoglobulin-like (IgSF) superfamily or the <span class="inline text-[1em] leading-7">C-type lectin</span>-like receptor (CTLR) superfamily.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Members of the IgSF family include the human killer cell immunoglobulin-like receptor (KIR) and the Immunoglobulin-like transcripts (ILT).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> CTLR inhibitory receptors include the CD94/NKG2A and the murine Ly49, which is probably <span class="inline text-[1em] leading-7">analogous</span> to the human KIR.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h3 id="role-in-t-cells" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Role in T cells<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">KIR and CD94 (CTLR) receptors are expressed by 5% of <span class="inline text-[1em] leading-7">peripheral blood T cells</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Killer immunoglobulin-like receptors on T cells have the function of signaling T cell activation. The KIRs are expressed on CD8+ T cells and will interact with the human leukocyte antigen (HLA) class I molecules on cells. The KIRs can signal the inhibitory or activate the signaling of the T cell and its ability to kill the foreign cells.</span>
<h2 id="nomenclature-and-classification" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Nomenclature and classification<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">KIR receptors are named based on the number of their extracellular Ig-like domains (2D or 3D) and by the length of their cytoplasmic tail (long (L), short (S), or pseudogene (P)).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_37qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> The number following the L, S, or P in the case of a pseudogene, differentiates KIR receptors with the same number of extracellular domains and length of cytoplasmic tail.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_67qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Finally, the asterisk after this nomenclature indicates allelic variants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Single substitutions, insertions, or deletions in the <span class="inline text-[1em] leading-7">genetic material</span> that encodes KIR receptors changes the site of termination for the gene, causing the cytoplasmic tail to be long or short, depending on the site of the stop codon.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> These single nucleotide alterations in the nucleotide sequence fundamentally alter KIR function. With the exception of KIR2DL4, which has both activating and inhibitory capabilities, KIR receptors with long cytoplasmic tails are inhibitory and those with short tails are activating.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_78abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h2 id="receptor-types" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Receptor types<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="inhibitory-receptors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Inhibitory receptors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Inhibitory receptors recognize self-MHC class I molecules on target self cells, causing the activation of signaling pathways that stop the cytolytic function of NK cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Self-MHC class I molecules are always expressed under normal circumstance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> According to the missing-self hypothesis, inhibitory KIR receptors recognize the downregulation of MHC class I molecules in virally-infected or transformed self cells, leading these receptors to stop sending the inhibition signal, which then leads to the lysis of these unhealthy cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_69qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Because natural killer cells target virally infected host cells and tumor cells, inhibitory KIR receptors are important in facilitating self-tolerance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">KIR inhibitory receptors signal through their immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic domain. When inhibitory KIR receptors bind to a ligand, their ITIMs are tyrosine phosphorylated and protein tyrosine phosphatases, including SHP-1, are recruited. The ITIMs are phosphorylated by the Src family kinases such as Lck and Fyn. The phosphatases dephosphorylate signals intermediates which blocks the activation and suppresses the cytotoxicity. It allows the natural killer cells to be deactivated when being in the presence of the healthy cells that are expressed in MHC class I levels. Inhibition occurs early in the activation signaling pathway, likely through the interference of the pathway by these phosphatases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h3 id="activating-receptors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Activating receptors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Activating receptors recognize ligands that indicate host cell aberration, including altered-self antigens (specific HLA class I allotypes, often similar to those recognized by inhibitory KIRs but with lower affinity) or potentially virus-induced ligands.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> The binding of activating KIR receptors to these molecules causes the activation of signaling pathways that cause NK cells to lyse virally infected or transformed cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Activating receptors do not have the immunoreceptor tyrosine-based inhibition motif (ITIM) characteristic of inhibitory receptors, and instead contain a positively charged lysine or arginine residue in their transmembrane domain (with the exception of KIR2DL4) that helps to bind DAP12, an adaptor molecule containing a negatively charged residue as well as immunoreceptor tyrosine-based activation motifs (ITAM).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Activating KIRs will rely on the DAP12 which is an adaptor molecule that will contain immunoreceptor tyrosine-based activation motifs (ITAMs). KIRs contain a positively charged lysine in the transmembrane which can form a salt bridge with the negatively charged DAP12&#x27;s acid and the ligand can signal to the tyrosine kinases such as SYK and ZAP-70 to create more activation signals. The activation signals would then lead to degranulation, cytokine production and the destruction of the target cells. The NK cell will only make a response depending how the inhibitory and activating signals work out, but the inhibitory signals have an overpower over the activating signals which will result in defense against cytotoxicity. Activating KIR receptors include KIR2DS, and KIR3DS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Much less is known about activating receptors compared to inhibitory receptors. A significant proportion of the human population lacks activating KIR receptors on the surface of their NK cells as a result of truncated variants of KIR2DS4 and 2DL4, which are not expressed on the cell surface, in individuals who are heterozygous for the KIR group A haplotype.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> This suggests that a lack of activating KIR receptors is not incredibly detrimental, likely because there are other families of activating NK cell surface receptors that bind MHC class I molecules that are probably expressed in individuals with this phenotype. Because little is known about the function of activating KIR receptors, however, it is possible that there is an important function of activating KIR receptors of which we are not yet aware.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Activating receptors have lower affinity for their ligands than do inhibitory receptors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Although the purpose of this difference in affinity is unknown, it is possible that the cytolysis of target cells occurs preferentially under conditions in which the expression of stimulating MHC class I molecules on target cells is high, which may occur during viral infection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> This difference, which is also present in Ly49, the murine homolog to KIR, tips the balance towards self-tolerance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<h3 id="expression" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Expression<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Activating and inhibitory KIR receptors are expressed on NK cells in patchy, variegated combinations, leading to distinct NK cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> KIR gene expression is regulated by mechanisms of DNA methylation. The IgSF and CTLR superfamily inhibitory receptors expressed on the surface of NK cells are each expressed on a subset of NK cells in such a way that not all classes of inhibitory NK cell receptors are expressed on each NK cell, but there is some overlap.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> This creates unique repertories of NK cells, increasing the specificity with which NK cells recognize virally-infected and transformed self-cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Expression of KIR receptors is determined primarily by genetic factors, but recent studies have found that epigenetic mechanisms also play a role in KIR receptor expression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Activating and inhibitory KIR receptors that recognize the same class I MHC molecule are mostly not expressed by the same NK cell.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_adqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> This pattern of expression is beneficial in that target cells that lack inhibitory MHC molecules but express activating MHC molecules are extremely sensitive to cytolysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Although initial expression of inhibitory and activating receptors on NK cells appears to be stochastic, there is an education process based on MHC class I alleles expressed by the host that determines the final repertoire of NK receptor expression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> This process of education is not well understood.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Different receptor genes are expressed primarily independently of other receptor genes, which substantiates the idea that initial expression of receptors is stochastic.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Receptors are not expressed entirely independently of each other, however, which supports the idea that there is an education process that reduces the amount of randomness associated with receptor expression. Further, once an NK receptor gene is activated in a cell, its expression is maintained for many cell generations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> It appears that some proportion of NK cells are developmentally immature and therefore lack inhibitory receptors, making them hyporesponsive to target cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> In the human fetal liver, KIR and CD49 receptors are already expressed by NK cells, indicating that at least some KIR receptors are present in fetal NK cells, although more studies are needed to substantiate this idea.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Although the induction of NK receptor expression is not fully understood, one study found that human progenitor cells cultured in vitro with cytokines developed into NK cells, and many of these cells expressed CD94/NKG2A receptors, a CTLR receptor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_geabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Moreover, there was little to no KIR receptor expression in these cells, so additional signals are clearly required for KIR induction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ieabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The balance between effective defense and self-tolerance is important to the functioning of NK cells. It is thought that NK cell self-tolerance is regulated by the educational process of receptor expression described above, although the exact mechanism is not known.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> The â€œat least oneâ€ hypothesis is an attractive, though not yet fully substantiated, hypothesis that tries to explain the way in which self-tolerance is regulated in the education process. This hypothesis posits that the NK cell repertoire is regulated so that at least one inhibitory receptor (either of the IgSF or CTLR superfamily) is present on every NK cell, which would ensure self-tolerance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Effective defense requires an opposing pattern of receptor expression. The co-expression of many MHC-specific receptors by NK cells is disfavored, likely because cells that co-express receptors are less able to attack virally infected or transformed cells that have down-regulated or lost one MHC molecule compared to NK cells that co-express receptors to a lesser degree.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Minimization of co-expression, therefore, is important for mounting an effective defense by maximizing the sensitivity of response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h1 id="killer-cell-immunoglobulin-like-receptor-structure" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Killer-cell Immunoglobulin-like Receptor Structure<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="structure" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Structure<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="gene-structure" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Gene structure<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The KIR gene cluster has approximately 150 <span class="inline text-[1em] leading-7">kb</span> and is located in the leukocyte receptor complex (LRC) on human <span class="inline text-[1em] leading-7">chromosome 19q</span>13.4.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> KIR genes have 8 or 9 exons, depending on whether they encode two or three extracellular Ig-like domains, which correspond to the protein domains (leader, D0/D1/D2, stem, transmembrane, and cytosolic domains with ITIMs or ITAMs).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Furthermore, the <span class="inline text-[1em] leading-7">promoter regions</span> of the KIR genes share greater than 90% sequence identity, which indicates that there is similar transcriptional regulation of KIR genes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_egqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The human killer cell immunoglobulin-like receptors superfamily (which share 35â€“50% sequence identity and the same fold as KIR) includes immunoglobulin-like transcripts (ILT, also known as <span class="inline text-[1em] leading-7">leukocyte immunoglobulin-like receptors</span> (LIRs)) and leukocyte-associated Ig-like receptors (LAIR).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Moreover, it has been reported that between 12 and 17 KIR receptors have been identified.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> The number of KIR genes varies by haplotype: the A haplotype typically has 14 loci, while B haplotypes can have expansions leading to more, with overall 15 distinct KIR genes identified across humans.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ahabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> There was a single ancestral gene from which all extant KIR receptor genes arose via duplications, recombinations, and mutations, and all KIR receptors share more than 90% sequence identity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_chabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<h4 id="genes" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Genes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">two domains, long cytoplasmic tail: <span class="inline text-[1em] leading-7">KIR2DL1</span>, KIR2DL2, <span class="inline text-[1em] leading-7">KIR2DL3</span>, <span class="inline text-[1em] leading-7">KIR2DL4</span>, KIR2DL5A, KIR2DL5B,</li>
<li class="text-[1em]">two domains, short cytoplasmic tail: <span class="inline text-[1em] leading-7">KIR2DS1</span>, KIR2DS2, KIR2DS3, <span class="inline text-[1em] leading-7">KIR2DS4</span>, KIR2DS5</li>
<li class="text-[1em]">three domains, long cytoplasmic tail: <span class="inline text-[1em] leading-7">KIR3DL1</span>, <span class="inline text-[1em] leading-7">KIR3DL2</span>, <span class="inline text-[1em] leading-7">KIR3DL3</span></li>
<li class="text-[1em]">three domains, short cytoplasmic tail: KIR3DS1</li>
</ul>
<h3 id="protein-structure" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Protein structure<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">NK cell receptors bind directly to the MHC class I molecules on the surface of target cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Human killer cell immunoglobulin-like receptors recognize the Î±1 and Î±2 domains of class I <span class="inline text-[1em] leading-7">human leukocyte antigens</span> (HLA-A, -B, and â€“C), which are the human versions of MHCs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> Position 44 in the D1 domain of KIR receptors and position 80 in HLA-C are important for the specificity of KIR-HLA binding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<h1 id="diversity" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Diversity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="allelic-diversity" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Allelic diversity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">All KIR genes have multiple alleles, though the pseudogenes KIR2DP1 (114 alleles) and KIR3DP1 (108 alleles) encode no functional proteins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> KIR3DL1 and KIR3DL2 are among the most polymorphic, with 307 and 252 alleles, respectively, as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> In total, as of 2024 there are 2219 known KIR alleles in the IPD-KIR database.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Further, inhibitory receptors are more polymorphic than activating receptors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> The great majority (69%) of substitutions in the KIR DNA sequence are nonsynonymous, and 31% are synonymous.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> The ratio of nonsynonymous to synonymous substitutions (dN/dS) is greater than one for every KIR and every KIR domain, indicating that positive selection is occurring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Further, the 5â€² exons, which encode the leader peptide and the Ig-like domains, have a larger proportion of nonsynonymous substitutions than do the 3â€² exons, which encode the stem, transmembrane region, and the cytoplasmic tail.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> This indicates that stronger selection is occurring on the 5â€² exons, which encode the extracellular part of the KIR that binds to the MHC.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> There is, therefore, evidence of strong selection on the KIR ligand binding sites, which is consistent with the high specificity of the KIR ligand binding site, as well as the rapid evolution of class I MHC molecules and viruses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<h2 id="genotype-and-haplotype-diversity" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Genotype and haplotype diversity<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Human genomes differ in their amount of KIR genes, in their proportion of inhibitory versus activating genes, and in their allelic variations of each gene.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> As a result of these polygenic and polymorphic variations, less than 2% of unrelated individuals have the same KIR genotype, and ethnic populations have broadly different KIR genotype frequencies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> This incredible diversity likely reflects the pressure from rapidly evolving viruses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Over 50 distinct haplotypes have been described, all of which can be broadly characterized by group A and group B haplotypes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> The Group A haplotype has a fixed set of genes, which are KIR3DL3, 2DL3, 2DP1, 2DL1, 3DP1, 2DL4, 3DL1, 2DS4, and 3DL2.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_alqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_blqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Group B haplotypes encompass all other haplotypes, and therefore have a variable set of genes, including several genes absent from group A, including KIR2DS1, 2DS2, 2DS3, 2DS5, 2DL2, 2DL5, and 3DS1.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_elqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Because group B has both gene and allelic diversity (compared to just allelic diversity in group A), group B is even more diverse than group A.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_glqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Four KIR genes (2DL4, 3DL2, 3DL3, and 3DP1) are present in nearly all KIR haplotypes and as a result are known as framework genes. Inheritance of maternal and paternal haplotypes results in further diversity of individual KIR genotype.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ilqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Group A only has one activating KIR receptor, whereas Group B contains many activating KIR receptors, and as a result group B haplotype carriers have a stronger response to virally infected and transformed cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> As a result of the huge migrations peoples indigenous to India, Australia, and the Americas made from Africa, activating KIR receptors became advantageous to these populations, and as a result these populations acquired activating KIR receptors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Studies of KIR genotypes across diverse populations have identified hundreds of distinct genotypes. For example, in a multi-ethnic cohort, high diversity was observed with rare genotypes unique to individuals, and the most common being homozygous group A.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Clearly, there is extensive diversity in human KIR genotypes, which allows for rapid evolution in response to rapidly evolving viruses.</span>
<h2 id="role-in-disease" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Role in disease<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Certain KIR genotypes influence susceptibility to various diseases. For example, the presence of activating KIR genes such as KIR2DS1 and KIR2DS2 has been associated with increased risk of specific autoimmune conditions, including psoriatic arthritis and type 1 diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The activating receptor KIR3DS1 has been linked to protective effects against hepatitis C virus (HCV) infection and slower progression of HIV/AIDS. Associations with cervical cancer are mixed, with some studies indicating higher frequency in cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The relationship between inhibitory and activating KIR genotypes and disease outcomes is complex, varying by disease type, stage, and interactions with HLA ligands.</span>
<h2 id="as-a-drug-target" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">As a drug target<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">1-7F9 (also known as IPH2101) is a fully human monoclonal antibody that binds to KIR2DL1, KIR2DL2, and KIR2DL3.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> Lirilumab (IPH2102/BMS-986015), a closely related second-generation version with improved stability, targets the same KIRs and is under investigation in clinical trials for the treatment of various cancers, including leukemia, multiple myeloma, and solid tumors, often in combination with other immunotherapies such as nivolumab.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup></span>
<h1 id="use-of-kirs-in-car-t-cell-therapy" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Use of KIRs in CAR T Cell Therapy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Killer-cell immunoglobulin-like receptors (KIRs) are being explored<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> as an alternative activation method in CAR T cell therapy. Unlike the traditional approach that utilizes T cell receptors, incorporating KIRs into CAR T cells aims to exploit the cytotoxic properties and regulatory functions of natural killer (NK) cells. This method is designed to mimic NK cell function, enhancing their ability to kill cells with missing MHC class I expression. It is under investigation for its potential to improve targeting and destruction of cancer cells, addressing limitations in current CAR T cell therapies such as off-target effects and resistance. Research is ongoing<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> to determine the effectiveness and safety of KIR-based activation in CAR T cell treatments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> As of 2025, the phase 1 STAR-101 trial evaluating SynKIR-110 in patients with mesothelin-expressing solid tumors is ongoing, with cohort 2 enrollment initiated this year.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Yawata M, Yawata N, Abi-Rached L, Parham P (2002). &quot;Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family&quot;. <em>Critical Reviews in Immunology</em>. <strong>22</strong> (5â€“6): 463â€“82. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12803322" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12803322</a>.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bashirova AA, Martin MP, McVicar DW, Carrington M (2006). <a href="https://doi.org/10.1146%2Fannurev.genom.7.080505.115726" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense&quot;</a>. <em>Annual Review of Genomics and Human Genetics</em>. <strong>7</strong> : 277â€“300. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev.genom.7.080505.115726" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev.genom.7.080505.115726</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16824023" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16824023</a>.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Wende H, Colonna M, Ziegler A, Volz A (1999). &quot;Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4&quot;. <em>Mammalian Genome</em>. <strong>10</strong> (2): 154â€“160. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs003359900961" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s003359900961</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/9922396" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9922396</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:25092393" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25092393</a>.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Roe, David; Vierra-Green, Cynthia; Pyo, Chul-Woo; Geraghty, Daniel E.; Spellman, Stephen R.; Maiers, Martin; Kuang, Rui (2020-11-18). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;A Detailed View of KIR Haplotype Structures and Gene Families as Provided by a New Motif-Based Multiple Sequence Alignment&quot;</a>. <em>Frontiers in Immunology</em>. <strong>11</strong>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3389%2Ffimmu.2020.585731" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3389/fimmu.2020.585731</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7708349</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/33312175" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33312175</a>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Raulet DH, Vance RE, McMahon CW (2001). &quot;Regulation of the natural killer cell receptor repertoire&quot;. <em>Annual Review of Immunology</em>. <strong>19</strong> : 291â€“330. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev.immunol.19.1.291" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev.immunol.19.1.291</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11244039" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11244039</a>.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vilches C, Parham P (2002). &quot;KIR: diverse, rapidly evolving receptors of innate and adaptive immunity&quot;. <em>Annual Review of Immunology</em>. <strong>20</strong> : 217â€“51. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev.immunol.20.092501.134942" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev.immunol.20.092501.134942</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11861603" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11861603</a>.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rajalingam R (2012). &quot;Overview of the killer cell Immunoglobulin-like receptor system&quot;. <em>Immunogenetics</em>. Methods in Molecular Biology. Vol. 882. pp. 3914â€“414. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2F978-1-61779-842-9_23" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/978-1-61779-842-9_23</a>. <span class="inline text-[1em] leading-7">ISBN</span> 978-1-61779-841-2. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22665247" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22665247</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Uhrberg M (January 2005). &quot;The KIR gene family: life in the fast lane of evolution&quot;. <em>European Journal of Immunology</em>. <strong>35</strong> (1): 10â€“5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Feji.200425743" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/eji.200425743</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15580655" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15580655</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:41486412" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">41486412</a>.</span></div></li><li id="https://www.ebi.ac.uk/ipd/kir/about/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ebi.ac.uk/ipd/kir/about/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ebi.ac.uk/ipd/kir/about/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK10135/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK10135/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK10135/</a></span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ljunggren HG, Karre K (1985). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187973" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Host resistance directed selectively against H-2 deficient lymphoma variants. Analysis of the mechanism&quot;</a>. <em>Journal of Experimental Medicine</em>. <strong>162</strong> (6): 1745â€“1759. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1084%2Fjem.162.6.1745" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1084/jem.162.6.1745</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187973" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2187973</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/3877776" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3877776</a>.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ljunggren HG, Karre K (1990). &quot;In search of the &quot;missing self&quot;. MHC molecules and NK cell recognition&quot;. <em>Immunology Today</em>. <strong>11</strong> (7): 237â€“244. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2F0167-5699%2890%2990097-S" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/0167-5699(90)90097-S</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/2201309" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2201309</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Moretta A, Bottino C, Vitale M, Pende, D, Biassoni R, Mingari MC, Moretta L (1996). &quot;Receptors for HLA-class I molecules in human Natural Killer cells&quot;. <em>Annual Review of Immunology</em>. <strong>14</strong> : 619â€“648. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev.immunol.14.1.619" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev.immunol.14.1.619</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/8717527" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8717527</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Biassoni R, Malnati MS (2018). &quot;Human Natural Killer Receptors, Co-Receptors, and their Ligands&quot;. <em>Current Protocols in Immunology</em>. <strong>121</strong> (1): e47. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fcpim.47" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/cpim.47</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30040219" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30040219</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:205710349" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">205710349</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, Bottino C, Moretta A (2001). &quot;Human natural killer cell receptors and co-receptors&quot;. <em>Immunological Reviews</em>. <strong>181</strong> : 203â€“214. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1034%2Fj.1600-065X.2001.1810117.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1034/j.1600-065X.2001.1810117.x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11513142" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11513142</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:24523974" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24523974</a>.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lanier LL (2005). &quot;NK cell recognition&quot;. <em>Annual Review of Immunology</em>. <strong>23</strong> : 225â€“274. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev.immunol.23.021704.115526" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev.immunol.23.021704.115526</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15771571" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15771571</a>.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868343" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Controlling natural killer cell responses: integration of signals for activation and inhibition&quot;</a>. <em>Annual Review of Immunology</em>. <strong>31</strong> : 227â€“258. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev-immunol-020711-075005" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev-immunol-020711-075005</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868343" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3868343</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23516982" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23516982</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Parham P (2005). &quot;MHC class I molecules and KIRs in human history, health and survival&quot;. <em>Nature Reviews Immunology</em>. <strong>5</strong> (3): 201â€“214. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fnri1570" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/nri1570</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15719024" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15719024</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:31182134" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31182134</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Raulet DH, Vance RE (2006). &quot;Self-tolerance of natural killer cells&quot;. <em>Nature Reviews Immunology</em>. <strong>6</strong> (7): 520â€“531. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fnri1863" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/nri1863</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16799471" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16799471</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:8652332" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8652332</a>.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati M, Vitale M, Bottino C, Moretta L, Moretta A, Long EO (1995). <a href="https://doi.org/10.1016%2F1074-7613%2895%2990025-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Molecular clones of the p58 Natural Killer cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains&quot;</a>. <em>Immunity</em>. <strong>2</strong> (5): 439â€“449. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2F1074-7613%2895%2990025-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/1074-7613(95)90025-x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7749980" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7749980</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Colonna M, Samaridis J (1995). &quot;Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells&quot;. <em>Science</em>. <strong>268</strong> (5209): 405â€“408. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/1995Sci...268..405C" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1995Sci...268..405C</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1126%2Fscience.7716543" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1126/science.7716543</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7716543" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7716543</a>.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Andre P, Biassoni R, Colonna M, Cosman D, Lanier LL, Long EO, Lopez-Botet M, Moretta A, Moretta L, Parham P, Trowsdale J, Vivier E, Wagtmann N, Wilson MJ (2001). <a href="https://doi.org/10.1038%2F90589" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;New nomenclature for MHC receptors&quot;</a>. <em>Nature Immunology</em>. <strong>2</strong> (8): 661. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2F90589" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/90589</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11477395" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11477395</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:32201997" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32201997</a>.</span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Yokoyama WM, Kim S, French AR (2004). &quot;The dynamic life of natural killer cells&quot;. <em>Annual Review of Immunology</em>. <strong>22</strong> : 405â€“429. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev.immunol.22.012703.104711" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev.immunol.22.012703.104711</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15032583" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15032583</a>.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Boyington JC, Sun PD (May 2002). &quot;A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors&quot;. <em>Molecular Immunology</em>. <strong>38</strong> (14): 1007â€“21. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fs0161-5890%2802%2900030-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/s0161-5890(02)00030-5</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11955593" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11955593</a>.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em><strong>aa</strong></em> <em><strong>ab</strong></em> <em><strong>ac</strong></em> <em><strong>ad</strong></em> <em><strong>ae</strong></em> <em><strong>af</strong></em> <em><strong>ag</strong></em> <em><strong>ah</strong></em> <em><strong>ai</strong></em> <em><strong>aj</strong></em> <em><strong>ak</strong></em> <em><strong>al</strong></em> <em><strong>am</strong></em> <em><strong>an</strong></em> <em><strong>ao</strong></em> <em><strong>ap</strong></em> <em><strong>aq</strong></em> <em><strong>ar</strong></em> <em><strong>as</strong></em> <em><strong>at</strong></em> <em><strong>au</strong></em> <em><strong>av</strong></em> <em><strong>aw</strong></em> Parham P (Feb 2005). &quot;Immunogenetics of killer cells immunoglobulin-like receptors&quot;. <em>Molecular Immunology</em>. <strong>42</strong> (4): 459â€“462. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.molimm.2004.07.027" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.molimm.2004.07.027</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15607799" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15607799</a>.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Radaev S, Sun PD (2003). &quot;Structure and function of natural killer cell surface receptors&quot;. <em>Annual Review of Biophysics and Biomolecular Structure</em>. <strong>32</strong> : 93â€“114. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev.biophys.32.110601.142347" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev.biophys.32.110601.142347</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12471063" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12471063</a>.</span></div></li><li id="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349/</a></span></div></li><li id="https://www.ebi.ac.uk/ipd/kir/about/statistics/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ebi.ac.uk/ipd/kir/about/statistics/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ebi.ac.uk/ipd/kir/about/statistics/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/tan.15307" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/tan.15307" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/tan.15307</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/22948769/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/22948769/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/22948769/</a></span></div></li><li id="https://doi.org/10.1002/art.38289" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1002/art.38289" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1002/art.38289</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/25941351/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/25941351/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/25941351/</a></span></div></li><li id="https://doi.org/10.3389/fimmu.2012.00326" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.3389/fimmu.2012.00326" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.3389/fimmu.2012.00326</a></span></div></li><li id="https://doi.org/10.1084/jem.20051845" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1084/jem.20051845" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1084/jem.20051845</a></span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">RomagnÃ© F, AndrÃ© P, Spee P, Zahn S, Anfossi N, Gauthier L, et al. (September 2009). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756126" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells&quot;</a>. <em>Blood</em>. <strong>114</strong> (13): 2667â€“77. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2009-02-206532" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2009-02-206532</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756126" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2756126</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19553639" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19553639</a>.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">World Health Organization</span> (2012). <a href="https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107&quot;</a> (PDF). <em>WHO Drug Information</em>. <strong>26</strong> (2).</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://www.ama-assn.org/resources/doc/usan/lirilumab.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab</a>, <em><span class="inline text-[1em] leading-7">American Medical Association</span></em>.</span></div></li><li id="https://immuno-oncologynews.com/lirilumab-iph2102bms-986015/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://immuno-oncologynews.com/lirilumab-iph2102bms-986015/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://immuno-oncologynews.com/lirilumab-iph2102bms-986015/</a></span></div></li><li id="https://clinicaltrials.gov/study/NCT03661320" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://clinicaltrials.gov/study/NCT03661320" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://clinicaltrials.gov/study/NCT03661320</a></span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-mesothelin-kir-car-transduced-t-cells-synkir-110" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Definition of autologous anti-mesothelin KIR-CAR-transduced T cells SynKIR-110&quot;</a>. <em><a href="http://www.cancer.gov" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.cancer.gov</a></em>. February 2, 2011. Retrieved 2024-06-05.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi; Bhoj, Vijay; Gershenson, Zack; Moon, Edmund; Newick, Kheng; Sun, Jing; Lo, Albert; Baradet, Timothy; Feldman, Michael D.; Barrett, David; PurÃ©, Ellen; Albelda, Steven; Milone, Michael C. (July 2015). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490943" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors&quot;</a>. <em>Cancer Immunology Research</em>. <strong>3</strong> (7): 815â€“826. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F2326-6066.CIR-15-0054" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/2326-6066.CIR-15-0054</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/2326-6066" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2326-6066</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490943" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4490943</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25941351" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25941351</a>.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Xu, Jun; Nunez-Cruz, Selene; Leferovich, John M.; Gulendran, Gayathri; Zhang, Chune; Yucel, Nora D.; Blair, Megan C.; Stanley, William S.; Johnson, Laura A.; Siegel, Don L.; Milone, Michael C. (2024-03-22). <a href="https://aacrjournals.org/cancerres/article/84/6_Supplement/6332/735622/Abstract-6332-Evaluating-the-relationship-of" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Abstract 6332: Evaluating the relationship of affinity, functional avidity, and in vivo potency in KIR-CAR T cells&quot;</a>. <em>Cancer Research</em>. <strong>84</strong> (6_Supplement): 6332. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F1538-7445.AM2024-6332" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/1538-7445.AM2024-6332</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1538-7445" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1538-7445</a>.</span></div></li><li id="31" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cgtlive.com/view/first-in-human-trial-kir-car-t-cell-therapy-msln-solid-tumors" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;First-in-Human Trial to Assess KIR-CAR T-Cell Therapy in MSLN+ Solid Tumors&quot;</a>. <em>CGTliveâ„¢</em>. 2022-09-25. Retrieved 2024-06-05.</span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Zhang, Qian; Nigel, Eric; Yu, Alvin; Hresko, Morgan; Minutolo, Nicholas; Powell, Daniel; Milone, Michael C. (2022-06-15). <a href="https://aacrjournals.org/cancerres/article/82/12_Supplement/5560/701358/Abstract-5560-KIR-based-CAR-design-showed-durable" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Abstract 5560: KIR-based CAR design showed durable antitumor efficacy by altered internalization kinetics following persistent antigenic stimulation&quot;</a>. <em>Cancer Research</em>. <strong>82</strong> (12_Supplement): 5560. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F1538-7445.AM2022-5560" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/1538-7445.AM2022-5560</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1538-7445" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1538-7445</a>.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Savello, Samantha (2022-09-27). <a href="https://pci.upenn.edu/penn-spinout-verismo-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-for-synkir-110-a-kir-car-t-cell-immunotherapy-candidate/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Penn Spinout Verismo Therapeutics Receives FDA Clearance of Investigational New Drug Application for SynKIR-110â„¢, a KIR-CAR T Cell Immunotherapy Candidate&quot;</a>. <em>Penn Center for Innovation</em>. Retrieved 2024-06-05.</span></div></li><li id="https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS5630" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS5630" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS5630</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Killer-cell_immunoglobulin-like_receptor" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz" id="_R_" async=""></script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Killer-cell_immunoglobulin-like_receptor\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Killer-cell_immunoglobulin-like_receptor\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Killer-cell_immunoglobulin-like_receptor\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T661c,"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"# Killer-cell immunoglobulin-like receptor\n\n| Identifiers | |\n|-------------|-|\n| Symbol | KIR |\n| [Membranome](Membranome_database \"Membranome database\") | [18](http://membranome.org/protein_families/18) |\n\n**Killer-cell immunoglobulin-like receptors** (**KIRs**), are a family of type I [transmembrane](Transmembrane_protein \"Transmembrane protein\") [glycoproteins](Glycoprotein \"Glycoprotein\") expressed on the [plasma membrane](Cell_membrane \"Cell membrane\") of [natural killer (NK)](Natural_killer_cell \"Natural killer cell\") cells and a minority of [T cells](T_cell \"T cell\").[1][2] In humans, they are encoded in the [leukocyte receptor complex](Leukocyte_receptor_complex \"Leukocyte receptor complex\") (LRC) on chromosome 19q13.4; the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.[3][4] NK cells use KIRs to detect perturbations or absence of self-HLA class I molecules on infected, transformed, or allogeneic cells, including in reproductive contexts such as pregnancy. The KIR receptors were originally defined serologically by the Moretta groups in the early 1990s. \n\nThey regulate the killing function of these cells by interacting with [major histocompatibility (MHC) class I](MHC_class_I \"MHC class I\") molecules, which are expressed on all nucleated cell types. KIR receptors can distinguish between MHC I allelic variants, which allows them to detect [virally](Virus \"Virus\") infected cells or [transformed cells](Malignant_transformation \"Malignant transformation\"). KIRs are [paired receptors](Paired_receptor \"Paired receptor\"), meaning some have activating and others have inhibitory functions; most KIRs are inhibitory: their recognition of MHC molecules suppresses the [cytotoxic](Cytotoxic \"Cytotoxic\") activity of their NK cell.[5] The receptors collaborate to monitor and respond to the changes in HLA class I antigen on cells of the body. \n\nA limited number of KIRs are activating: their recognition of MHC molecules activates the cytotoxic activity of their cell.[6] Initial expression of KIRs on NK cells is [stochastic](Stochastic \"Stochastic\"), but NK cells undergo an educational process as they mature that alters the KIR expression to maximize the balance between effective defense and self-tolerance. KIR's role in killing unhealthy self-cells and not killing healthy self-cells, involves them in protection against and propensity to viral infections such as HIV, HCV, autoimmune disease, and cancer.[2][7] KIR molecules are [polymorphic](Polymorphism_\\(biology\\) \"Polymorphism \\(biology\\)\"): their [gene](Gene \"Gene\") sequences differ greatly across individuals. They are also [polygenic](Quantitative_genetics \"Quantitative genetics\") so that it is rare for two unrelated individuals to possess the same KIR genotype.[8] Below is a list of the 16 KIR genes: \n\n| KIR gene | Signalling     | Ligand          |\n|----------|----------------|-----------------|\n| 2DL1     | Inhibitory     | HLA-C2          |\n| 2DL2     | Inhibitory     | HLA-C1          |\n| 2DL3     | Inhibitory     | HLA-C1          |\n| 2DL4     | Activating     | HLA-G           |\n| 2DL5A    | Inhibitory     | Unknown         |\n| 2DL5B    | Inhibitory     | Unknown         |\n| 3DL1     | Inhibitory     | HLA-Bw4         |\n| 3DL2     | Inhibitory     | HLA-A3, A11     |\n| 3DL3     | Inhibitory     | Unknown         |\n| 2DS1     | Activating     | HLA-C2          |\n| 2DS2     | Activating     | HLA-C1          |\n| 2DS3     | Activating     | Unknown         |\n| 2DS4     | Activating     | HLA-C1          |\n| 2DS5     | Activating     | Unknown         |\n| 3DS1     | Activating     | HLA-Bw4         |\n| 2DP1     | Pseudogene     | -               |\n| 3DP1     | Pseudogene     | -               |[](https://www.ebi.ac.uk/ipd/kir/about/)[](https://www.ncbi.nlm.nih.gov/books/NBK10135/)\n\nUnlike T lymphocytes, resting NK cells use preformed lytic granules to kill target cells, implying a rapid cytolytic effect that requires a finely regulated control mechanism. The ability to spare normal tissues, but not transformed cells, is termed the \"[missing self](Missing_self \"Missing self\")\" hypothesis.[9][10] This phenomenon is determined by MHC class Iâ€“specific inhibitory receptors that functionally dominate the triggering potentials induced by activating receptors.[11][12] Thus, NK cells use a complex array of inhibitory or activating receptor/ligand interactions, the balance of which regulates NK cell function and cytolytic activity.[11][13][14][15][16][17] Receptors displaying this function evolved during phylogenesis following the rapid evolution of genes coding for MHC class I molecules. Thus, in primates and a few other species, evolved MHC class Iâ€“inhibitory receptors belong to the KIR immunoglobulin superfamily,[18][19][20] while in rodents and other species the same function is under the control of type II integral transmembrane glycoproteins, structurally characterized as disulfide-linked homodimers belonging to the [Ly49](Ly49 \"Ly49\") protein family.[21] The factors controlling and regulating KIR expression on NK cells are not well understood. It is accepted that tolerance is a major driving force. Tolerance is a fundamental feature of the immune system and is required to prevent a system designed for attack from damaging itself.\n# Killer-cell Immunoglobulin-like Receptors: Function\n\n## Function\n\n### Role in natural killer cells\n\n[Natural killer (NK) cells](Natural_killer_cell \"Natural killer cell\") are a type of [lymphocyte](Lymphocyte \"Lymphocyte\") cell involved in the [innate immune system's](Innate_immune_system \"Innate immune system\") response to viral infection and tumor transformation of host cells.[20][7] Like T cells, NK cells have many qualities characteristic of the [adaptive immune system](Adaptive_immune_system \"Adaptive immune system\"), including the production of â€œmemoryâ€ cells that persist following encounter with [antigens](Antigen \"Antigen\") and the ability to create a secondary recall response.[7] Unlike T cells, NK cell receptors are [germline](Germline \"Germline\") encoded, and therefore do not require [somatic](Somatic_cell \"Somatic cell\") gene rearrangements.[7] Because NK cells target self cells, they have an intricate mechanism by which they differentiate self and non-self cells in order to minimize the destruction of healthy cells and maximize the destruction of unhealthy cells.[20]\n\nNatural killer cell [cytolysis](Cytolysis \"Cytolysis\") of target cells and [cytokine](Cytokine \"Cytokine\") production is controlled by a balance of inhibitory and activating signals, which are facilitated by NK cell receptors.[20][22][23] NK cell inhibitory receptors are part of either the immunoglobulin-like (IgSF) superfamily or the [C-type lectin](C-type_lectin \"C-type lectin\")-like receptor (CTLR) superfamily.[20][7] Members of the IgSF family include the human killer cell immunoglobulin-like receptor (KIR) and the Immunoglobulin-like transcripts (ILT).[7] CTLR inhibitory receptors include the CD94/NKG2A and the murine Ly49, which is probably [analogous](Analogy \"Analogy\") to the human KIR.[23][5]\n\n### Role in T cells\n\nKIR and CD94 (CTLR) receptors are expressed by 5% of [peripheral blood T cells](Peripheral_blood_lymphocyte \"Peripheral blood lymphocyte\").[12][23] Killer immunoglobulin-like receptors on T cells have the function of signaling T cell activation. The KIRs are expressed on CD8+ T cells and will interact with the human leukocyte antigen (HLA) class I molecules on cells. The KIRs can signal the inhibitory or activate the signaling of the T cell and its ability to kill the foreign cells.\n## Nomenclature and classification\n\nKIR receptors are named based on the number of their extracellular Ig-like domains (2D or 3D) and by the length of their cytoplasmic tail (long (L), short (S), or pseudogene (P)).[12][23] The number following the L, S, or P in the case of a pseudogene, differentiates KIR receptors with the same number of extracellular domains and length of cytoplasmic tail.[3][23] Finally, the asterisk after this nomenclature indicates allelic variants.[5][23]\n\nSingle substitutions, insertions, or deletions in the [genetic material](DNA \"DNA\") that encodes KIR receptors changes the site of termination for the gene, causing the cytoplasmic tail to be long or short, depending on the site of the stop codon.[12][3] These single nucleotide alterations in the nucleotide sequence fundamentally alter KIR function. With the exception of KIR2DL4, which has both activating and inhibitory capabilities, KIR receptors with long cytoplasmic tails are inhibitory and those with short tails are activating.[20][23]\n## Receptor types\n\n### Inhibitory receptors\n\nInhibitory receptors recognize self-MHC class I molecules on target self cells, causing the activation of signaling pathways that stop the cytolytic function of NK cells.[24] Self-MHC class I molecules are always expressed under normal circumstance.[20] According to the missing-self hypothesis, inhibitory KIR receptors recognize the downregulation of MHC class I molecules in virally-infected or transformed self cells, leading these receptors to stop sending the inhibition signal, which then leads to the lysis of these unhealthy cells.[20][23] Because natural killer cells target virally infected host cells and tumor cells, inhibitory KIR receptors are important in facilitating self-tolerance.[6]\n\nKIR inhibitory receptors signal through their immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic domain. When inhibitory KIR receptors bind to a ligand, their ITIMs are tyrosine phosphorylated and protein tyrosine phosphatases, including SHP-1, are recruited. The ITIMs are phosphorylated by the Src family kinases such as Lck and Fyn. The phosphatases dephosphorylate signals intermediates which blocks the activation and suppresses the cytotoxicity. It allows the natural killer cells to be deactivated when being in the presence of the healthy cells that are expressed in MHC class I levels. Inhibition occurs early in the activation signaling pathway, likely through the interference of the pathway by these phosphatases.[20][23]\n\n### Activating receptors\n\nActivating receptors recognize ligands that indicate host cell aberration, including altered-self antigens (specific HLA class I allotypes, often similar to those recognized by inhibitory KIRs but with lower affinity) or potentially virus-induced ligands.[20][23] The binding of activating KIR receptors to these molecules causes the activation of signaling pathways that cause NK cells to lyse virally infected or transformed cells.[23]\n\nActivating receptors do not have the immunoreceptor tyrosine-based inhibition motif (ITIM) characteristic of inhibitory receptors, and instead contain a positively charged lysine or arginine residue in their transmembrane domain (with the exception of KIR2DL4) that helps to bind DAP12, an adaptor molecule containing a negatively charged residue as well as immunoreceptor tyrosine-based activation motifs (ITAM).[23][13] Activating KIRs will rely on the DAP12 which is an adaptor molecule that will contain immunoreceptor tyrosine-based activation motifs (ITAMs). KIRs contain a positively charged lysine in the transmembrane which can form a salt bridge with the negatively charged DAP12's acid and the ligand can signal to the tyrosine kinases such as SYK and ZAP-70 to create more activation signals. The activation signals would then lead to degranulation, cytokine production and the destruction of the target cells. The NK cell will only make a response depending how the inhibitory and activating signals work out, but the inhibitory signals have an overpower over the activating signals which will result in defense against cytotoxicity. Activating KIR receptors include KIR2DS, and KIR3DS.[23]\n\nMuch less is known about activating receptors compared to inhibitory receptors. A significant proportion of the human population lacks activating KIR receptors on the surface of their NK cells as a result of truncated variants of KIR2DS4 and 2DL4, which are not expressed on the cell surface, in individuals who are heterozygous for the KIR group A haplotype.[20] This suggests that a lack of activating KIR receptors is not incredibly detrimental, likely because there are other families of activating NK cell surface receptors that bind MHC class I molecules that are probably expressed in individuals with this phenotype. Because little is known about the function of activating KIR receptors, however, it is possible that there is an important function of activating KIR receptors of which we are not yet aware.[20]\n\nActivating receptors have lower affinity for their ligands than do inhibitory receptors.[23] Although the purpose of this difference in affinity is unknown, it is possible that the cytolysis of target cells occurs preferentially under conditions in which the expression of stimulating MHC class I molecules on target cells is high, which may occur during viral infection.[23] This difference, which is also present in Ly49, the murine homolog to KIR, tips the balance towards self-tolerance.[17]\n\n### Expression\n\nActivating and inhibitory KIR receptors are expressed on NK cells in patchy, variegated combinations, leading to distinct NK cells.[23] KIR gene expression is regulated by mechanisms of DNA methylation. The IgSF and CTLR superfamily inhibitory receptors expressed on the surface of NK cells are each expressed on a subset of NK cells in such a way that not all classes of inhibitory NK cell receptors are expressed on each NK cell, but there is some overlap.[23] This creates unique repertories of NK cells, increasing the specificity with which NK cells recognize virally-infected and transformed self-cells.[23] Expression of KIR receptors is determined primarily by genetic factors, but recent studies have found that epigenetic mechanisms also play a role in KIR receptor expression.[23] Activating and inhibitory KIR receptors that recognize the same class I MHC molecule are mostly not expressed by the same NK cell.[23] This pattern of expression is beneficial in that target cells that lack inhibitory MHC molecules but express activating MHC molecules are extremely sensitive to cytolysis.[23]\n\nAlthough initial expression of inhibitory and activating receptors on NK cells appears to be stochastic, there is an education process based on MHC class I alleles expressed by the host that determines the final repertoire of NK receptor expression.[23][12] This process of education is not well understood.[23] Different receptor genes are expressed primarily independently of other receptor genes, which substantiates the idea that initial expression of receptors is stochastic.[23] Receptors are not expressed entirely independently of each other, however, which supports the idea that there is an education process that reduces the amount of randomness associated with receptor expression. Further, once an NK receptor gene is activated in a cell, its expression is maintained for many cell generations.[12][23] It appears that some proportion of NK cells are developmentally immature and therefore lack inhibitory receptors, making them hyporesponsive to target cells.[23] In the human fetal liver, KIR and CD49 receptors are already expressed by NK cells, indicating that at least some KIR receptors are present in fetal NK cells, although more studies are needed to substantiate this idea.[23] Although the induction of NK receptor expression is not fully understood, one study found that human progenitor cells cultured in vitro with cytokines developed into NK cells, and many of these cells expressed CD94/NKG2A receptors, a CTLR receptor.[23] Moreover, there was little to no KIR receptor expression in these cells, so additional signals are clearly required for KIR induction.[23]\n\nThe balance between effective defense and self-tolerance is important to the functioning of NK cells. It is thought that NK cell self-tolerance is regulated by the educational process of receptor expression described above, although the exact mechanism is not known.[23] The â€œat least oneâ€ hypothesis is an attractive, though not yet fully substantiated, hypothesis that tries to explain the way in which self-tolerance is regulated in the education process. This hypothesis posits that the NK cell repertoire is regulated so that at least one inhibitory receptor (either of the IgSF or CTLR superfamily) is present on every NK cell, which would ensure self-tolerance.[23] Effective defense requires an opposing pattern of receptor expression. The co-expression of many MHC-specific receptors by NK cells is disfavored, likely because cells that co-express receptors are less able to attack virally infected or transformed cells that have down-regulated or lost one MHC molecule compared to NK cells that co-express receptors to a lesser degree.[23] Minimization of co-expression, therefore, is important for mounting an effective defense by maximizing the sensitivity of response.[23]\n# Killer-cell Immunoglobulin-like Receptor Structure\n\n## Structure\n\n### Gene structure\n\nThe KIR gene cluster has approximately 150 [kb](Kilobase \"Kilobase\") and is located in the leukocyte receptor complex (LRC) on human [chromosome 19q](Chromosome_19 \"Chromosome 19\")13.4.[1][24][12] KIR genes have 8 or 9 exons, depending on whether they encode two or three extracellular Ig-like domains, which correspond to the protein domains (leader, D0/D1/D2, stem, transmembrane, and cytosolic domains with ITIMs or ITAMs).[20] Furthermore, the [promoter regions](Promoter_\\(genetics\\) \"Promoter \\(genetics\\)\") of the KIR genes share greater than 90% sequence identity, which indicates that there is similar transcriptional regulation of KIR genes.[20]\n\nThe human killer cell immunoglobulin-like receptors superfamily (which share 35â€“50% sequence identity and the same fold as KIR) includes immunoglobulin-like transcripts (ILT, also known as [leukocyte immunoglobulin-like receptors](Leukocyte_immunoglobulin-like_receptors \"Leukocyte immunoglobulin-like receptors\") (LIRs)) and leukocyte-associated Ig-like receptors (LAIR).[3] Moreover, it has been reported that between 12 and 17 KIR receptors have been identified.[3][23][12] The number of KIR genes varies by haplotype: the A haplotype typically has 14 loci, while B haplotypes can have expansions leading to more, with overall 15 distinct KIR genes identified across humans.[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349/) There was a single ancestral gene from which all extant KIR receptor genes arose via duplications, recombinations, and mutations, and all KIR receptors share more than 90% sequence identity.[20]\n\n#### Genes\n\n- two domains, long cytoplasmic tail: [KIR2DL1](KIR2DL1 \"KIR2DL1\"), KIR2DL2, [KIR2DL3](Killer_cell_immunoglobulin-like_receptor_2DL3 \"Killer cell immunoglobulin-like receptor 2DL3\"), [KIR2DL4](KIR2DL4 \"KIR2DL4\"), KIR2DL5A, KIR2DL5B,\n- two domains, short cytoplasmic tail: [KIR2DS1](KIR2DS1 \"KIR2DS1\"), KIR2DS2, KIR2DS3, [KIR2DS4](KIR2DS4 \"KIR2DS4\"), KIR2DS5\n- three domains, long cytoplasmic tail: [KIR3DL1](KIR3DL1 \"KIR3DL1\"), [KIR3DL2](KIR3DL2 \"KIR3DL2\"), [KIR3DL3](KIR3DL3 \"KIR3DL3\")\n- three domains, short cytoplasmic tail: KIR3DS1\n\n### Protein structure\n\nNK cell receptors bind directly to the MHC class I molecules on the surface of target cells.[23] Human killer cell immunoglobulin-like receptors recognize the Î±1 and Î±2 domains of class I [human leukocyte antigens](Human_leukocyte_antigen \"Human leukocyte antigen\") (HLA-A, -B, and â€“C), which are the human versions of MHCs.[23][12] Position 44 in the D1 domain of KIR receptors and position 80 in HLA-C are important for the specificity of KIR-HLA binding.[12]\n# Diversity\n\n## Allelic diversity\n\nAll KIR genes have multiple alleles, though the pseudogenes KIR2DP1 (114 alleles) and KIR3DP1 (108 alleles) encode no functional proteins.[](https://www.ebi.ac.uk/ipd/kir/about/statistics/)[](https://onlinelibrary.wiley.com/doi/10.1111/tan.15307) KIR3DL1 and KIR3DL2 are among the most polymorphic, with 307 and 252 alleles, respectively, as of 2024.[](https://www.ebi.ac.uk/ipd/kir/about/statistics/) In total, as of 2024 there are 2219 known KIR alleles in the IPD-KIR database.[](https://www.ebi.ac.uk/ipd/kir/about/statistics/) Further, inhibitory receptors are more polymorphic than activating receptors.[23] The great majority (69%) of substitutions in the KIR DNA sequence are nonsynonymous, and 31% are synonymous.[6] The ratio of nonsynonymous to synonymous substitutions (dN/dS) is greater than one for every KIR and every KIR domain, indicating that positive selection is occurring.[6] Further, the 5â€² exons, which encode the leader peptide and the Ig-like domains, have a larger proportion of nonsynonymous substitutions than do the 3â€² exons, which encode the stem, transmembrane region, and the cytoplasmic tail.[6] This indicates that stronger selection is occurring on the 5â€² exons, which encode the extracellular part of the KIR that binds to the MHC.[6] There is, therefore, evidence of strong selection on the KIR ligand binding sites, which is consistent with the high specificity of the KIR ligand binding site, as well as the rapid evolution of class I MHC molecules and viruses.[6][23]\n\n## Genotype and haplotype diversity\n\nHuman genomes differ in their amount of KIR genes, in their proportion of inhibitory versus activating genes, and in their allelic variations of each gene.[8] As a result of these polygenic and polymorphic variations, less than 2% of unrelated individuals have the same KIR genotype, and ethnic populations have broadly different KIR genotype frequencies.[8] This incredible diversity likely reflects the pressure from rapidly evolving viruses.[23] Over 50 distinct haplotypes have been described, all of which can be broadly characterized by group A and group B haplotypes.[](https://pubmed.ncbi.nlm.nih.gov/22948769/) The Group A haplotype has a fixed set of genes, which are KIR3DL3, 2DL3, 2DP1, 2DL1, 3DP1, 2DL4, 3DL1, 2DS4, and 3DL2.[20][23] Group B haplotypes encompass all other haplotypes, and therefore have a variable set of genes, including several genes absent from group A, including KIR2DS1, 2DS2, 2DS3, 2DS5, 2DL2, 2DL5, and 3DS1.[20][23] Because group B has both gene and allelic diversity (compared to just allelic diversity in group A), group B is even more diverse than group A.[20] Four KIR genes (2DL4, 3DL2, 3DL3, and 3DP1) are present in nearly all KIR haplotypes and as a result are known as framework genes. Inheritance of maternal and paternal haplotypes results in further diversity of individual KIR genotype.[23]\n\nGroup A only has one activating KIR receptor, whereas Group B contains many activating KIR receptors, and as a result group B haplotype carriers have a stronger response to virally infected and transformed cells.[23] As a result of the huge migrations peoples indigenous to India, Australia, and the Americas made from Africa, activating KIR receptors became advantageous to these populations, and as a result these populations acquired activating KIR receptors.[23]\n\nStudies of KIR genotypes across diverse populations have identified hundreds of distinct genotypes. For example, in a multi-ethnic cohort, high diversity was observed with rare genotypes unique to individuals, and the most common being homozygous group A.[5] Clearly, there is extensive diversity in human KIR genotypes, which allows for rapid evolution in response to rapidly evolving viruses.\n## Role in disease\n\nCertain KIR genotypes influence susceptibility to various diseases. For example, the presence of activating KIR genes such as KIR2DS1 and KIR2DS2 has been associated with increased risk of specific autoimmune conditions, including psoriatic arthritis and type 1 diabetes.[](https://doi.org/10.1002/art.38289)[](https://pubmed.ncbi.nlm.nih.gov/25941351/)\n\nThe activating receptor KIR3DS1 has been linked to protective effects against hepatitis C virus (HCV) infection and slower progression of HIV/AIDS. Associations with cervical cancer are mixed, with some studies indicating higher frequency in cases.[](https://doi.org/10.3389/fimmu.2012.00326)[](https://doi.org/10.1084/jem.20051845)\n\nThe relationship between inhibitory and activating KIR genotypes and disease outcomes is complex, varying by disease type, stage, and interactions with HLA ligands.\n## As a drug target\n\n1-7F9 (also known as IPH2101) is a fully human monoclonal antibody that binds to KIR2DL1, KIR2DL2, and KIR2DL3.[25] Lirilumab (IPH2102/BMS-986015), a closely related second-generation version with improved stability, targets the same KIRs and is under investigation in clinical trials for the treatment of various cancers, including leukemia, multiple myeloma, and solid tumors, often in combination with other immunotherapies such as nivolumab.[26][27][](https://immuno-oncologynews.com/lirilumab-iph2102bms-986015/)[](https://clinicaltrials.gov/study/NCT03661320)\n# Use of KIRs in CAR T Cell Therapy\n\nKiller-cell immunoglobulin-like receptors (KIRs) are being explored[28][29][30] as an alternative activation method in CAR T cell therapy. Unlike the traditional approach that utilizes T cell receptors, incorporating KIRs into CAR T cells aims to exploit the cytotoxic properties and regulatory functions of natural killer (NK) cells. This method is designed to mimic NK cell function, enhancing their ability to kill cells with missing MHC class I expression. It is under investigation for its potential to improve targeting and destruction of cancer cells, addressing limitations in current CAR T cell therapies such as off-target effects and resistance. Research is ongoing[31][32] to determine the effectiveness and safety of KIR-based activation in CAR T cell treatments.[33] As of 2025, the phase 1 STAR-101 trial evaluating SynKIR-110 in patients with mesothelin-expressing solid tumors is ongoing, with cohort 2 enrollment initiated this year.[](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS5630)"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761882490365,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"_**a**_ _**b**_ Yawata M, Yawata N, Abi-Rached L, Parham P (2002). \\\"Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family\\\". _Critical Reviews in Immunology_. **22** (5â€“6): 463â€“82\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12803322](https://pubmed.ncbi.nlm.nih.gov/12803322).\",\"description\":\"1. ^ _**a**_ _**b**_ Yawata M, Yawata N, Abi-Rached L, Parham P (2002). \\\"Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family\\\". _Critical Reviews in Immunology_. **22** (5â€“6): 463â€“82\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12803322](https://pubmed.ncbi.nlm.nih.gov/12803322).\",\"url\":\"PMID_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ Bashirova AA, Martin MP, McVicar DW, Carrington M (2006). [\\\"The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense\\\"](https://doi.org/10.1146%2Fannurev.genom.7.080505.115726). _Annual Review of Genomics and Human Genetics_. **7** : 277â€“300\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.genom.7.080505.115726](https://doi.org/10.1146%2Fannurev.genom.7.080505.115726). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16824023](https://pubmed.ncbi.nlm.nih.gov/16824023).\",\"description\":\"2. ^ _**a**_ _**b**_ Bashirova AA, Martin MP, McVicar DW, Carrington M (2006). [\\\"The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense\\\"](https://doi.org/10.1146%2Fannurev.genom.7.080505.115726). _Annual Review of Genomics and Human Genetics_. **7** : 277â€“300\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.genom.7.080505.115726](https://doi.org/10.1146%2Fannurev.genom.7.080505.115726). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16824023](https://pubmed.ncbi.nlm.nih.gov/16824023).\",\"url\":\"https://doi.org/10.1146%2Fannurev.genom.7.080505.115726\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Wende H, Colonna M, Ziegler A, Volz A (1999). \\\"Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4\\\". _Mammalian Genome_. **10** (2): 154â€“160\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s003359900961](https://doi.org/10.1007%2Fs003359900961). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9922396](https://pubmed.ncbi.nlm.nih.gov/9922396). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25092393](https://api.semanticscholar.org/CorpusID:25092393).\",\"description\":\"3. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Wende H, Colonna M, Ziegler A, Volz A (1999). \\\"Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4\\\". _Mammalian Genome_. **10** (2): 154â€“160\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s003359900961](https://doi.org/10.1007%2Fs003359900961). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9922396](https://pubmed.ncbi.nlm.nih.gov/9922396). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [25092393](https://api.semanticscholar.org/CorpusID:25092393).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** Roe, David; Vierra-Green, Cynthia; Pyo, Chul-Woo; Geraghty, Daniel E.; Spellman, Stephen R.; Maiers, Martin; Kuang, Rui (2020-11-18). [\\\"A Detailed View of KIR Haplotype Structures and Gene Families as Provided by a New Motif-Based Multiple Sequence Alignment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349). _Frontiers in Immunology_. **11**. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fimmu.2020.585731](https://doi.org/10.3389%2Ffimmu.2020.585731). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7708349](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33312175](https://pubmed.ncbi.nlm.nih.gov/33312175).\",\"description\":\"4. **^** Roe, David; Vierra-Green, Cynthia; Pyo, Chul-Woo; Geraghty, Daniel E.; Spellman, Stephen R.; Maiers, Martin; Kuang, Rui (2020-11-18). [\\\"A Detailed View of KIR Haplotype Structures and Gene Families as Provided by a New Motif-Based Multiple Sequence Alignment\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349). _Frontiers in Immunology_. **11**. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fimmu.2020.585731](https://doi.org/10.3389%2Ffimmu.2020.585731). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7708349](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33312175](https://pubmed.ncbi.nlm.nih.gov/33312175).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Raulet DH, Vance RE, McMahon CW (2001). \\\"Regulation of the natural killer cell receptor repertoire\\\". _Annual Review of Immunology_. **19** : 291â€“330\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.19.1.291](https://doi.org/10.1146%2Fannurev.immunol.19.1.291). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11244039](https://pubmed.ncbi.nlm.nih.gov/11244039).\",\"description\":\"5. ^ _**a**_ _**b**_ _**c**_ _**d**_ Raulet DH, Vance RE, McMahon CW (2001). \\\"Regulation of the natural killer cell receptor repertoire\\\". _Annual Review of Immunology_. **19** : 291â€“330\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.19.1.291](https://doi.org/10.1146%2Fannurev.immunol.19.1.291). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11244039](https://pubmed.ncbi.nlm.nih.gov/11244039).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ Vilches C, Parham P (2002). \\\"KIR: diverse, rapidly evolving receptors of innate and adaptive immunity\\\". _Annual Review of Immunology_. **20** : 217â€“51\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.20.092501.134942](https://doi.org/10.1146%2Fannurev.immunol.20.092501.134942). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11861603](https://pubmed.ncbi.nlm.nih.gov/11861603).\",\"description\":\"6. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ Vilches C, Parham P (2002). \\\"KIR: diverse, rapidly evolving receptors of innate and adaptive immunity\\\". _Annual Review of Immunology_. **20** : 217â€“51\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.20.092501.134942](https://doi.org/10.1146%2Fannurev.immunol.20.092501.134942). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11861603](https://pubmed.ncbi.nlm.nih.gov/11861603).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Rajalingam R (2012). \\\"Overview of the killer cell Immunoglobulin-like receptor system\\\". _Immunogenetics_. Methods in Molecular Biology. Vol. 882\\\\. pp. 3914â€“414\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/978-1-61779-842-9_23](https://doi.org/10.1007%2F978-1-61779-842-9_23). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-61779-841-2. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22665247](https://pubmed.ncbi.nlm.nih.gov/22665247).\",\"description\":\"7. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Rajalingam R (2012). \\\"Overview of the killer cell Immunoglobulin-like receptor system\\\". _Immunogenetics_. Methods in Molecular Biology. Vol. 882\\\\. pp. 3914â€“414\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/978-1-61779-842-9_23](https://doi.org/10.1007%2F978-1-61779-842-9_23). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-1-61779-841-2. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22665247](https://pubmed.ncbi.nlm.nih.gov/22665247).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"_**a**_ _**b**_ Uhrberg M (January 2005). \\\"The KIR gene family: life in the fast lane of evolution\\\". _European Journal of Immunology_. **35** (1): 10â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/eji.200425743](https://doi.org/10.1002%2Feji.200425743). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15580655](https://pubmed.ncbi.nlm.nih.gov/15580655). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [41486412](https://api.semanticscholar.org/CorpusID:41486412).\",\"description\":\"8. ^ _**a**_ _**b**_ Uhrberg M (January 2005). \\\"The KIR gene family: life in the fast lane of evolution\\\". _European Journal of Immunology_. **35** (1): 10â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/eji.200425743](https://doi.org/10.1002%2Feji.200425743). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15580655](https://pubmed.ncbi.nlm.nih.gov/15580655). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [41486412](https://api.semanticscholar.org/CorpusID:41486412).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** Ljunggren HG, Karre K (1985). [\\\"Host resistance directed selectively against H-2 deficient lymphoma variants. Analysis of the mechanism\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187973). _Journal of Experimental Medicine_. **162** (6): 1745â€“1759\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.162.6.1745](https://doi.org/10.1084%2Fjem.162.6.1745). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2187973](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187973). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3877776](https://pubmed.ncbi.nlm.nih.gov/3877776).\",\"description\":\"9. **^** Ljunggren HG, Karre K (1985). [\\\"Host resistance directed selectively against H-2 deficient lymphoma variants. Analysis of the mechanism\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187973). _Journal of Experimental Medicine_. **162** (6): 1745â€“1759\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1084/jem.162.6.1745](https://doi.org/10.1084%2Fjem.162.6.1745). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2187973](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187973). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3877776](https://pubmed.ncbi.nlm.nih.gov/3877776).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187973\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"_**a**_ _**b**_ _**c**_ Ljunggren HG, Karre K (1990). \\\"In search of the \\\"missing self\\\". MHC molecules and NK cell recognition\\\". _Immunology Today_. **11** (7): 237â€“244\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0167-5699(90)90097-S](https://doi.org/10.1016%2F0167-5699%2890%2990097-S). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2201309](https://pubmed.ncbi.nlm.nih.gov/2201309).\",\"description\":\"10. ^ _**a**_ _**b**_ _**c**_ Ljunggren HG, Karre K (1990). \\\"In search of the \\\"missing self\\\". MHC molecules and NK cell recognition\\\". _Immunology Today_. **11** (7): 237â€“244\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0167-5699(90)90097-S](https://doi.org/10.1016%2F0167-5699%2890%2990097-S). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2201309](https://pubmed.ncbi.nlm.nih.gov/2201309).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"_**a**_ _**b**_ Moretta A, Bottino C, Vitale M, Pende, D, Biassoni R, Mingari MC, Moretta L (1996). \\\"Receptors for HLA-class I molecules in human Natural Killer cells\\\". _Annual Review of Immunology_. **14** : 619â€“648\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.14.1.619](https://doi.org/10.1146%2Fannurev.immunol.14.1.619). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8717527](https://pubmed.ncbi.nlm.nih.gov/8717527).\",\"description\":\"11. ^ _**a**_ _**b**_ Moretta A, Bottino C, Vitale M, Pende, D, Biassoni R, Mingari MC, Moretta L (1996). \\\"Receptors for HLA-class I molecules in human Natural Killer cells\\\". _Annual Review of Immunology_. **14** : 619â€“648\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.14.1.619](https://doi.org/10.1146%2Fannurev.immunol.14.1.619). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8717527](https://pubmed.ncbi.nlm.nih.gov/8717527).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ Biassoni R, Malnati MS (2018). \\\"Human Natural Killer Receptors, Co-Receptors, and their Ligands\\\". _Current Protocols in Immunology_. **121** (1): e47. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cpim.47](https://doi.org/10.1002%2Fcpim.47). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30040219](https://pubmed.ncbi.nlm.nih.gov/30040219). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [205710349](https://api.semanticscholar.org/CorpusID:205710349).\",\"description\":\"12. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ Biassoni R, Malnati MS (2018). \\\"Human Natural Killer Receptors, Co-Receptors, and their Ligands\\\". _Current Protocols in Immunology_. **121** (1): e47. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cpim.47](https://doi.org/10.1002%2Fcpim.47). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30040219](https://pubmed.ncbi.nlm.nih.gov/30040219). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [205710349](https://api.semanticscholar.org/CorpusID:205710349).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"_**a**_ _**b**_ Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, Bottino C, Moretta A (2001). \\\"Human natural killer cell receptors and co-receptors\\\". _Immunological Reviews_. **181** : 203â€“214\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1034/j.1600-065X.2001.1810117.x](https://doi.org/10.1034%2Fj.1600-065X.2001.1810117.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11513142](https://pubmed.ncbi.nlm.nih.gov/11513142). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [24523974](https://api.semanticscholar.org/CorpusID:24523974).\",\"description\":\"13. ^ _**a**_ _**b**_ Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, Bottino C, Moretta A (2001). \\\"Human natural killer cell receptors and co-receptors\\\". _Immunological Reviews_. **181** : 203â€“214\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1034/j.1600-065X.2001.1810117.x](https://doi.org/10.1034%2Fj.1600-065X.2001.1810117.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11513142](https://pubmed.ncbi.nlm.nih.gov/11513142). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [24523974](https://api.semanticscholar.org/CorpusID:24523974).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** Lanier LL (2005). \\\"NK cell recognition\\\". _Annual Review of Immunology_. **23** : 225â€“274\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.23.021704.115526](https://doi.org/10.1146%2Fannurev.immunol.23.021704.115526). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15771571](https://pubmed.ncbi.nlm.nih.gov/15771571).\",\"description\":\"14. **^** Lanier LL (2005). \\\"NK cell recognition\\\". _Annual Review of Immunology_. **23** : 225â€“274\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.23.021704.115526](https://doi.org/10.1146%2Fannurev.immunol.23.021704.115526). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15771571](https://pubmed.ncbi.nlm.nih.gov/15771571).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013). [\\\"Controlling natural killer cell responses: integration of signals for activation and inhibition\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868343). _Annual Review of Immunology_. **31** : 227â€“258\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev-immunol-020711-075005](https://doi.org/10.1146%2Fannurev-immunol-020711-075005). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3868343](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868343). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23516982](https://pubmed.ncbi.nlm.nih.gov/23516982).\",\"description\":\"15. **^** Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013). [\\\"Controlling natural killer cell responses: integration of signals for activation and inhibition\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868343). _Annual Review of Immunology_. **31** : 227â€“258\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev-immunol-020711-075005](https://doi.org/10.1146%2Fannurev-immunol-020711-075005). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3868343](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868343). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23516982](https://pubmed.ncbi.nlm.nih.gov/23516982).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868343\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Parham P (2005). \\\"MHC class I molecules and KIRs in human history, health and survival\\\". _Nature Reviews Immunology_. **5** (3): 201â€“214\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nri1570](https://doi.org/10.1038%2Fnri1570). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15719024](https://pubmed.ncbi.nlm.nih.gov/15719024). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [31182134](https://api.semanticscholar.org/CorpusID:31182134).\",\"description\":\"16. **^** Parham P (2005). \\\"MHC class I molecules and KIRs in human history, health and survival\\\". _Nature Reviews Immunology_. **5** (3): 201â€“214\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nri1570](https://doi.org/10.1038%2Fnri1570). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15719024](https://pubmed.ncbi.nlm.nih.gov/15719024). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [31182134](https://api.semanticscholar.org/CorpusID:31182134).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"_**a**_ _**b**_ Raulet DH, Vance RE (2006). \\\"Self-tolerance of natural killer cells\\\". _Nature Reviews Immunology_. **6** (7): 520â€“531\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nri1863](https://doi.org/10.1038%2Fnri1863). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16799471](https://pubmed.ncbi.nlm.nih.gov/16799471). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [8652332](https://api.semanticscholar.org/CorpusID:8652332).\",\"description\":\"17. ^ _**a**_ _**b**_ Raulet DH, Vance RE (2006). \\\"Self-tolerance of natural killer cells\\\". _Nature Reviews Immunology_. **6** (7): 520â€“531\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nri1863](https://doi.org/10.1038%2Fnri1863). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16799471](https://pubmed.ncbi.nlm.nih.gov/16799471). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [8652332](https://api.semanticscholar.org/CorpusID:8652332).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati M, Vitale M, Bottino C, Moretta L, Moretta A, Long EO (1995). [\\\"Molecular clones of the p58 Natural Killer cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains\\\"](https://doi.org/10.1016%2F1074-7613%2895%2990025-x). _Immunity_. **2** (5): 439â€“449\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/1074-7613(95)90025-x](https://doi.org/10.1016%2F1074-7613%2895%2990025-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7749980](https://pubmed.ncbi.nlm.nih.gov/7749980).\",\"description\":\"18. **^** Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati M, Vitale M, Bottino C, Moretta L, Moretta A, Long EO (1995). [\\\"Molecular clones of the p58 Natural Killer cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains\\\"](https://doi.org/10.1016%2F1074-7613%2895%2990025-x). _Immunity_. **2** (5): 439â€“449\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/1074-7613(95)90025-x](https://doi.org/10.1016%2F1074-7613%2895%2990025-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7749980](https://pubmed.ncbi.nlm.nih.gov/7749980).\",\"url\":\"https://doi.org/10.1016%2F1074-7613%2895%2990025-x\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Colonna M, Samaridis J (1995). \\\"Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells\\\". _Science_. **268** (5209): 405â€“408\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1995Sci...268..405C](https://ui.adsabs.harvard.edu/abs/1995Sci...268..405C). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.7716543](https://doi.org/10.1126%2Fscience.7716543). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7716543](https://pubmed.ncbi.nlm.nih.gov/7716543).\",\"description\":\"19. **^** Colonna M, Samaridis J (1995). \\\"Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells\\\". _Science_. **268** (5209): 405â€“408\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1995Sci...268..405C](https://ui.adsabs.harvard.edu/abs/1995Sci...268..405C). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.7716543](https://doi.org/10.1126%2Fscience.7716543). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7716543](https://pubmed.ncbi.nlm.nih.gov/7716543).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ Andre P, Biassoni R, Colonna M, Cosman D, Lanier LL, Long EO, Lopez-Botet M, Moretta A, Moretta L, Parham P, Trowsdale J, Vivier E, Wagtmann N, Wilson MJ (2001). [\\\"New nomenclature for MHC receptors\\\"](https://doi.org/10.1038%2F90589). _Nature Immunology_. **2** (8): 661. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/90589](https://doi.org/10.1038%2F90589). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11477395](https://pubmed.ncbi.nlm.nih.gov/11477395). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [32201997](https://api.semanticscholar.org/CorpusID:32201997).\",\"description\":\"20. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ Andre P, Biassoni R, Colonna M, Cosman D, Lanier LL, Long EO, Lopez-Botet M, Moretta A, Moretta L, Parham P, Trowsdale J, Vivier E, Wagtmann N, Wilson MJ (2001). [\\\"New nomenclature for MHC receptors\\\"](https://doi.org/10.1038%2F90589). _Nature Immunology_. **2** (8): 661. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/90589](https://doi.org/10.1038%2F90589). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11477395](https://pubmed.ncbi.nlm.nih.gov/11477395). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [32201997](https://api.semanticscholar.org/CorpusID:32201997).\",\"url\":\"https://doi.org/10.1038%2F90589\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Yokoyama WM, Kim S, French AR (2004). \\\"The dynamic life of natural killer cells\\\". _Annual Review of Immunology_. **22** : 405â€“429\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.22.012703.104711](https://doi.org/10.1146%2Fannurev.immunol.22.012703.104711). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15032583](https://pubmed.ncbi.nlm.nih.gov/15032583).\",\"description\":\"21. **^** Yokoyama WM, Kim S, French AR (2004). \\\"The dynamic life of natural killer cells\\\". _Annual Review of Immunology_. **22** : 405â€“429\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.immunol.22.012703.104711](https://doi.org/10.1146%2Fannurev.immunol.22.012703.104711). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15032583](https://pubmed.ncbi.nlm.nih.gov/15032583).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** Boyington JC, Sun PD (May 2002). \\\"A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors\\\". _Molecular Immunology_. **38** (14): 1007â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/s0161-5890(02)00030-5](https://doi.org/10.1016%2Fs0161-5890%2802%2900030-5). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11955593](https://pubmed.ncbi.nlm.nih.gov/11955593).\",\"description\":\"22. **^** Boyington JC, Sun PD (May 2002). \\\"A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors\\\". _Molecular Immunology_. **38** (14): 1007â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/s0161-5890(02)00030-5](https://doi.org/10.1016%2Fs0161-5890%2802%2900030-5). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11955593](https://pubmed.ncbi.nlm.nih.gov/11955593).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ _**x**_ _**y**_ _**z**_ _**aa**_ _**ab**_ _**ac**_ _**ad**_ _**ae**_ _**af**_ _**ag**_ _**ah**_ _**ai**_ _**aj**_ _**ak**_ _**al**_ _**am**_ _**an**_ _**ao**_ _**ap**_ _**aq**_ _**ar**_ _**as**_ _**at**_ _**au**_ _**av**_ _**aw**_ Parham P (Feb 2005). \\\"Immunogenetics of killer cells immunoglobulin-like receptors\\\". _Molecular Immunology_. **42** (4): 459â€“462\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.molimm.2004.07.027](https://doi.org/10.1016%2Fj.molimm.2004.07.027). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15607799](https://pubmed.ncbi.nlm.nih.gov/15607799).\",\"description\":\"23. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ _**x**_ _**y**_ _**z**_ _**aa**_ _**ab**_ _**ac**_ _**ad**_ _**ae**_ _**af**_ _**ag**_ _**ah**_ _**ai**_ _**aj**_ _**ak**_ _**al**_ _**am**_ _**an**_ _**ao**_ _**ap**_ _**aq**_ _**ar**_ _**as**_ _**at**_ _**au**_ _**av**_ _**aw**_ Parham P (Feb 2005). \\\"Immunogenetics of killer cells immunoglobulin-like receptors\\\". _Molecular Immunology_. **42** (4): 459â€“462\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.molimm.2004.07.027](https://doi.org/10.1016%2Fj.molimm.2004.07.027). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15607799](https://pubmed.ncbi.nlm.nih.gov/15607799).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"_**a**_ _**b**_ Radaev S, Sun PD (2003). \\\"Structure and function of natural killer cell surface receptors\\\". _Annual Review of Biophysics and Biomolecular Structure_. **32** : 93â€“114\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.biophys.32.110601.142347](https://doi.org/10.1146%2Fannurev.biophys.32.110601.142347). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12471063](https://pubmed.ncbi.nlm.nih.gov/12471063).\",\"description\":\"24. ^ _**a**_ _**b**_ Radaev S, Sun PD (2003). \\\"Structure and function of natural killer cell surface receptors\\\". _Annual Review of Biophysics and Biomolecular Structure_. **32** : 93â€“114\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.biophys.32.110601.142347](https://doi.org/10.1146%2Fannurev.biophys.32.110601.142347). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12471063](https://pubmed.ncbi.nlm.nih.gov/12471063).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** RomagnÃ© F, AndrÃ© P, Spee P, Zahn S, Anfossi N, Gauthier L, et al. (September 2009). [\\\"Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756126). _Blood_. **114** (13): 2667â€“77\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2009-02-206532](https://doi.org/10.1182%2Fblood-2009-02-206532). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2756126](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756126). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19553639](https://pubmed.ncbi.nlm.nih.gov/19553639).\",\"description\":\"25. **^** RomagnÃ© F, AndrÃ© P, Spee P, Zahn S, Anfossi N, Gauthier L, et al. (September 2009). [\\\"Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756126). _Blood_. **114** (13): 2667â€“77\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2009-02-206532](https://doi.org/10.1182%2Fblood-2009-02-206532). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2756126](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756126). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19553639](https://pubmed.ncbi.nlm.nih.gov/19553639).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756126\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** [World Health Organization](World_Health_Organization \\\"World Health Organization\\\") (2012). [\\\"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107\\\"](https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf) (PDF). _WHO Drug Information_. **26** (2).\",\"description\":\"26. **^** [World Health Organization](World_Health_Organization \\\"World Health Organization\\\") (2012). [\\\"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107\\\"](https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf) (PDF). _WHO Drug Information_. **26** (2).\",\"url\":\"World_Health_Organization \\\"World Health Organization\\\"\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** [Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab](http://www.ama-assn.org/resources/doc/usan/lirilumab.pdf), _[American Medical Association](American_Medical_Association \\\"American Medical Association\\\")_.\",\"description\":\"27. **^** [Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab](http://www.ama-assn.org/resources/doc/usan/lirilumab.pdf), _[American Medical Association](American_Medical_Association \\\"American Medical Association\\\")_.\",\"url\":\"http://www.ama-assn.org/resources/doc/usan/lirilumab.pdf\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** [\\\"Definition of autologous anti-mesothelin KIR-CAR-transduced T cells SynKIR-110\\\"](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-mesothelin-kir-car-transduced-t-cells-synkir-110). _www.cancer.gov_. February 2, 2011. Retrieved 2024-06-05.\",\"description\":\"28. **^** [\\\"Definition of autologous anti-mesothelin KIR-CAR-transduced T cells SynKIR-110\\\"](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-mesothelin-kir-car-transduced-t-cells-synkir-110). _www.cancer.gov_. February 2, 2011. Retrieved 2024-06-05.\",\"url\":\"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-mesothelin-kir-car-transduced-t-cells-synkir-110\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi; Bhoj, Vijay; Gershenson, Zack; Moon, Edmund; Newick, Kheng; Sun, Jing; Lo, Albert; Baradet, Timothy; Feldman, Michael D.; Barrett, David; PurÃ©, Ellen; Albelda, Steven; Milone, Michael C. (July 2015). [\\\"Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490943). _Cancer Immunology Research_. **3** (7): 815â€“826\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2326-6066.CIR-15-0054](https://doi.org/10.1158%2F2326-6066.CIR-15-0054). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2326-6066](https://search.worldcat.org/issn/2326-6066). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4490943](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490943). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25941351](https://pubmed.ncbi.nlm.nih.gov/25941351).\",\"description\":\"29. **^** Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi; Bhoj, Vijay; Gershenson, Zack; Moon, Edmund; Newick, Kheng; Sun, Jing; Lo, Albert; Baradet, Timothy; Feldman, Michael D.; Barrett, David; PurÃ©, Ellen; Albelda, Steven; Milone, Michael C. (July 2015). [\\\"Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490943). _Cancer Immunology Research_. **3** (7): 815â€“826\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2326-6066.CIR-15-0054](https://doi.org/10.1158%2F2326-6066.CIR-15-0054). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [2326-6066](https://search.worldcat.org/issn/2326-6066). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4490943](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490943). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25941351](https://pubmed.ncbi.nlm.nih.gov/25941351).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490943\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** Xu, Jun; Nunez-Cruz, Selene; Leferovich, John M.; Gulendran, Gayathri; Zhang, Chune; Yucel, Nora D.; Blair, Megan C.; Stanley, William S.; Johnson, Laura A.; Siegel, Don L.; Milone, Michael C. (2024-03-22). [\\\"Abstract 6332: Evaluating the relationship of affinity, functional avidity, and in vivo potency in KIR-CAR T cells\\\"](https://aacrjournals.org/cancerres/article/84/6_Supplement/6332/735622/Abstract-6332-Evaluating-the-relationship-of). _Cancer Research_. **84** (6_Supplement): 6332. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/1538-7445.AM2024-6332](https://doi.org/10.1158%2F1538-7445.AM2024-6332). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1538-7445](https://search.worldcat.org/issn/1538-7445).\",\"description\":\"30. **^** Xu, Jun; Nunez-Cruz, Selene; Leferovich, John M.; Gulendran, Gayathri; Zhang, Chune; Yucel, Nora D.; Blair, Megan C.; Stanley, William S.; Johnson, Laura A.; Siegel, Don L.; Milone, Michael C. (2024-03-22). [\\\"Abstract 6332: Evaluating the relationship of affinity, functional avidity, and in vivo potency in KIR-CAR T cells\\\"](https://aacrjournals.org/cancerres/article/84/6_Supplement/6332/735622/Abstract-6332-Evaluating-the-relationship-of). _Cancer Research_. **84** (6_Supplement): 6332. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/1538-7445.AM2024-6332](https://doi.org/10.1158%2F1538-7445.AM2024-6332). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1538-7445](https://search.worldcat.org/issn/1538-7445).\",\"url\":\"https://aacrjournals.org/cancerres/article/84/6_Supplement/6332/735622/Abstract-6332-Evaluating-the-relationship-of\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"** [\\\"First-in-Human Trial to Assess KIR-CAR T-Cell Therapy in MSLN+ Solid Tumors\\\"](https://www.cgtlive.com/view/first-in-human-trial-kir-car-t-cell-therapy-msln-solid-tumors). _CGTliveâ„¢_. 2022-09-25. Retrieved 2024-06-05.\",\"description\":\"31. **^** [\\\"First-in-Human Trial to Assess KIR-CAR T-Cell Therapy in MSLN+ Solid Tumors\\\"](https://www.cgtlive.com/view/first-in-human-trial-kir-car-t-cell-therapy-msln-solid-tumors). _CGTliveâ„¢_. 2022-09-25. Retrieved 2024-06-05.\",\"url\":\"https://www.cgtlive.com/view/first-in-human-trial-kir-car-t-cell-therapy-msln-solid-tumors\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** Zhang, Qian; Nigel, Eric; Yu, Alvin; Hresko, Morgan; Minutolo, Nicholas; Powell, Daniel; Milone, Michael C. (2022-06-15). [\\\"Abstract 5560: KIR-based CAR design showed durable antitumor efficacy by altered internalization kinetics following persistent antigenic stimulation\\\"](https://aacrjournals.org/cancerres/article/82/12_Supplement/5560/701358/Abstract-5560-KIR-based-CAR-design-showed-durable). _Cancer Research_. **82** (12_Supplement): 5560. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/1538-7445.AM2022-5560](https://doi.org/10.1158%2F1538-7445.AM2022-5560). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1538-7445](https://search.worldcat.org/issn/1538-7445).\",\"description\":\"32. **^** Zhang, Qian; Nigel, Eric; Yu, Alvin; Hresko, Morgan; Minutolo, Nicholas; Powell, Daniel; Milone, Michael C. (2022-06-15). [\\\"Abstract 5560: KIR-based CAR design showed durable antitumor efficacy by altered internalization kinetics following persistent antigenic stimulation\\\"](https://aacrjournals.org/cancerres/article/82/12_Supplement/5560/701358/Abstract-5560-KIR-based-CAR-design-showed-durable). _Cancer Research_. **82** (12_Supplement): 5560. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/1538-7445.AM2022-5560](https://doi.org/10.1158%2F1538-7445.AM2022-5560). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1538-7445](https://search.worldcat.org/issn/1538-7445).\",\"url\":\"https://aacrjournals.org/cancerres/article/82/12_Supplement/5560/701358/Abstract-5560-KIR-based-CAR-design-showed-durable\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Savello, Samantha (2022-09-27). [\\\"Penn Spinout Verismo Therapeutics Receives FDA Clearance of Investigational New Drug Application for SynKIR-110â„¢, a KIR-CAR T Cell Immunotherapy Candidate\\\"](https://pci.upenn.edu/penn-spinout-verismo-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-for-synkir-110-a-kir-car-t-cell-immunotherapy-candidate/). _Penn Center for Innovation_. Retrieved 2024-06-05.\",\"description\":\"33. **^** Savello, Samantha (2022-09-27). [\\\"Penn Spinout Verismo Therapeutics Receives FDA Clearance of Investigational New Drug Application for SynKIR-110â„¢, a KIR-CAR T Cell Immunotherapy Candidate\\\"](https://pci.upenn.edu/penn-spinout-verismo-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-for-synkir-110-a-kir-car-t-cell-immunotherapy-candidate/). _Penn Center for Innovation_. Retrieved 2024-06-05.\",\"url\":\"https://pci.upenn.edu/penn-spinout-verismo-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-for-synkir-110-a-kir-car-t-cell-immunotherapy-candidate/\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"the KIR region is approximately 150 kilobases and contains 14 loci, including 7 protein-coding genes (some duplicated) and 2 pseudogenes.\",\"explanation\":\"The stated numbers are inaccurate; the KIR gene cluster contains 16 genes, including 14 that encode functional proteins (8 inhibitory, 6 activating) and 2 pseudogenes, spanning approximately 150 kb.\",\"fixedText\":\"Correct to: the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.\",\"evidenceSource\":\"[](https://www.nature.com/articles/s41598-020-61702-y)\"},{\"criticality\":\"Critical\",\"issueType\":\"Internal Contradiction\",\"problematicText\":\"Below will be a list of the 16 KIR genes:\",\"explanation\":\"The introductory description mentions 14 loci with 7 protein-coding genes, but the table introduction claims 16 KIR genes, creating inconsistency in gene count.\",\"fixedText\":\"Align the introductory count with 16 genes including 2 pseudogenes, and ensure the table lists all 16 appropriately.\",\"evidenceSource\":\"Existing ref #3 and #4; [](https://www.nature.com/articles/s41598-020-61702-y)\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"KIR gene | Signalling | Ligand | Antibody 2DL1 | Inhibitory | HLA-C2 | EB6, HP-MA4 2DL3 (including 2 DL2) | Inhibitory | HLA-C1 | GL183, DX27 ... 2DS4 | Activatory | not known | 5.133\",\"explanation\":\"The table inaccurately combines 2DL2 and 2DL3 (separate genes, both inhibitory for HLA-C1), lists incorrect or outdated ligands (e.g., 2DS4 binds HLA-C group 1 alleles like C*0102; 3DS1 binds HLA-Bw4), omits some genes (e.g., explicit 2DL2), and the antibody column is not essential for encyclopedic summary; total listed does not match 16.\",\"fixedText\":\"Rewrite table in markdown to list 16 entries separately (including pseudogenes), correct signaling and ligands based on current knowledge (e.g., separate 2DL2 and 2DL3, update 2DS4 to HLA-C1, 3DS1 to HLA-Bw4), remove antibody column to focus on key info, cite sources inline if added.\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/books/NBK10135/); [](https://www.ebi.ac.uk/ipd/kir/about/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"NK cells in humans use the KIRs to the perturbations from self-HLA class I molecules present on infected or HLA-disparate fetal transplants.\",\"explanation\":\"Sentence is grammatically incorrect and unclear; KIRs detect absence or alteration (\\\"missing self\\\" or perturbations) in self-HLA class I on infected/transformed cells; \\\"HLA-disparate fetal transplants\\\" misstates role in pregnancy tolerance (KIR-HLA interactions at maternal-fetal interface prevent rejection).\",\"fixedText\":\"Rephrase to: \\\"NK cells use KIRs to detect perturbations or absence of self-HLA class I molecules on infected, transformed, or allogeneic cells, including in reproductive contexts like pregnancy.\\\"\",\"evidenceSource\":\"Existing ref #5, #9, #10\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific text; overall table and description]\",\"explanation\":\"The table and description lack separation of distinct genes like 2DL2 and 2DL3, and updated ligand information for activating KIRs (e.g., 2DS4's HLA-C specificity confirmed post-2000s); as of 2025, no major new KIR genes, but precision improves neutrality and accuracy.\",\"fixedText\":\"Add missing genes (e.g., explicit 2DL2), update ligands (2DS4: HLA-C1; confirm others as unknown where applicable).\",\"evidenceSource\":\"[](https://www.ebi.ac.uk/ipd/kir/about/); [](https://www.ncbi.nlm.nih.gov/books/NBK10135/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"including induced-self antigens (which are markers of infected self cells and include MICA, MICB, and ULBP, all of which are related to MHC class 1 molecules), altered-self antigens (MHC class I antigens laden with foreign peptide), and/or non-self (pathogen encoded molecules).\",\"explanation\":\"KIR activating receptors primarily recognize specific HLA class I allotypes, similar to inhibitory KIRs. MICA, MICB, and ULBP are stress-induced ligands for the NKG2D receptor, not KIRs. Non-self pathogen molecules are not typical KIR ligands; some activating KIRs may recognize virus-induced changes in HLA, but the description misattributes ligands.\",\"fixedText\":\"Revise to: Activating receptors recognize specific HLA class I molecules, often the same allotypes as their inhibitory counterparts but with lower affinity, or potentially virus-induced ligands on altered HLA.\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3044898/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"Entire \\\"**Evolution of KIRs in Different Species**\\\" subsection, starting from \\\"KIRs are a prime example...\\\" to the end.\",\"explanation\":\"This content duplicates the evolutionary discussion in the article introduction (citing refs [18-21]) and does not align with the article structure, where \\\"Receptor types\\\" focuses on human KIR inhibitory, activating, and expression, while diversity and evolution are covered elsewhere (e.g., Diversity section).\",\"fixedText\":\"Remove the entire subsection to avoid duplication and maintain section scope.\",\"evidenceSource\":\"Article structure provided\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"The HLA class I regulated control of NK cell function can be exploited in an allogeneic bone marrow transplantation setting to eradicate acute myeloid leukemias**.\",\"explanation\":\"This describes a clinical application of KIR-HLA interactions, which belongs in the \\\"Role in disease\\\" section per the article structure, not under receptor expression.\",\"fixedText\":\"Remove the sentence as it is out of scope for this section.\",\"evidenceSource\":\"Article structure provided\"},{\"criticality\":\"Critical\",\"issueType\":\"Internal Contradiction\",\"problematicText\":\"Activating KIRs will rely on the DAP12 which is an adaptor molecule... The activation signals would then lead to degranulation, cytokine production and the destruction of the target cells. The NK cell will only make a response depending how the inhibitory and activating signals work out, but the inhibitory signals have an overpower over the activating signals which will result in defense against cytotoxicity. Inhibition occurs early in the activation signaling pathway, likely through the interference of the pathway by these phosphatases.\",\"explanation\":\"This detailed description of activating KIR signaling (DAP12, ITAM, SYK, ZAP-70) is placed in the \\\"Inhibitory receptors\\\" subsection, creating confusion and contradicting the subsection's focus on inhibitory mechanisms (ITIM, SHP-1). It belongs in the activating subsection.\",\"fixedText\":\"Move the activating signaling description to the \\\"Activating receptors\\\" subsection and integrate it properly after the existing signaling info.\",\"evidenceSource\":\"[23]\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"KIR genes have 9 exons, which are strongly correlated with KIR receptor protein domains (leader, D0, D1, and D2, stem, transmembrane, and cytosolic domains).\",\"explanation\":\"2-domain KIR genes (e.g., KIR2DL1, KIR2DS1) have 8 exons, lacking the exon for the D0 domain, while 3-domain KIR genes have 9 exons. This inaccuracy misrepresents the gene structure.\",\"fixedText\":\"Revise to: \\\"KIR genes have 8 or 9 exons, depending on whether they encode two or three extracellular Ig-like domains, which correspond to the protein domains (leader, D0/D1/D2, stem, transmembrane, and cytosolic domains with ITIMs or ITAMs).\\\"\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/books/NBK10135/figure/A390/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"The human killer cell immunoglobulin-like receptors superfamily (which share 35â€“50% sequence identity and the same fold as KIR) includes immunoglobulin-like transcripts (ILT, also known as leukocyte immunoglobulin-like receptors (LIRs)), leukocyte-associated Ig-like receptors (LAIR), paired Ig-like receptors (PIR), and gp49.\",\"explanation\":\"PIR and gp49 are rodent (murine) proteins, not part of the human KIR superfamily. The human LRC includes KIR, LILR (ILT/LIR), and LAIR, but not PIR or gp49, which are mouse orthologs.\",\"fixedText\":\"Remove reference to PIR and gp49: \\\"...includes immunoglobulin-like transcripts (ILT, also known as leukocyte immunoglobulin-like receptors (LIRs)) and leukocyte-associated Ig-like receptors (LAIR).\\\"\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2192985/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"The entire subsection titled \\\"Scientists were able to discover that HLA-C2 does not influence the overall frequency of KIR2DS1+ NK cells.\\\" including the paragraph on antibody staining method.\",\"explanation\":\"No citation is provided for the claims about the discovery and the experimental method using mAbs 143211 and EB6. The content describes a specific 2010 study but lacks sourcing, violating verifiability.\",\"fixedText\":\"Add citation to Yu et al. (2010), but since content does not pertain to structure, remove the entire subsection to avoid duplication with other sections like Function or Diversity.\",\"evidenceSource\":\"[](https://ashpublications.org/blood/article/115/6/1166/26504/Education-of-human-natural-killer-cells-by)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"The entire subsection titled \\\"Scientists were able to discover that HLA-C2 does not influence the overall frequency of KIR2DS1+ NK cells.\\\"\",\"explanation\":\"This subsection discusses NK cell frequency, education, and detection methods, which do not relate to gene or protein structure. It is misplaced in the Structure section and better suited to sections like Function (Role in natural killer cells) or Diversity.\",\"fixedText\":\"Remove the subsection entirely from the Structure section.\",\"evidenceSource\":\"Article structure provided\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No explicit description of the variable number of KIR loci across haplotypes.\",\"explanation\":\"The text mentions \\\"between 12 and 17 KIR receptors,\\\" but lacks precision on haplotype variation (A vs. B haplotypes), which is key to understanding KIR gene structure diversity. Current knowledge (as of 2020) identifies 15 KIR genes/loci in the region, with copy number variation.\",\"fixedText\":\"Add: \\\"The number of KIR genes varies by haplotype: the A haplotype typically has 14 loci, while B haplotypes can have expansions leading to more, with overall 15 distinct KIR genes identified across humans.\\\"\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708349/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"In total, as of 2012 there were 614 known KIR nucleotide sequences encoding 321 distinct KIR proteins.[23]\\\"\",\"explanation\":\"The data is outdated; the reference [23] is from 2005, and current IPD-KIR database (release 2.14, 2024) reports 2219 alleles. This affects the understanding of current allelic diversity.\",\"fixedText\":\"Update to current total: as of 2024, there are 2219 known KIR alleles encoding distinct proteins (exact protein count not specified, but alleles are the key metric). Cite IPD-KIR.\",\"evidenceSource\":\"[] (https://www.ebi.ac.uk/ipd/kir/about/statistics/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"\\\"with KIR3DL2 and KIR3DL1 having the most variations (12 and 11, respectively).[6]\\\"\",\"explanation\":\"Outdated counts from 2002 reference [6]; current IPD-KIR data shows KIR3DL2 has 252 alleles and KIR3DL1 has 307 alleles, significantly altering the perception of polymorphism levels.\",\"fixedText\":\"Update to: KIR3DL1 and KIR3DL2 are among the most polymorphic, with 307 and 252 alleles, respectively, as of 2024.\",\"evidenceSource\":\"[] (https://www.ebi.ac.uk/ipd/kir/about/statistics/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"All but two KIR genes (KIR2DP1 and KIR3DL3) have multiple alleles\\\"\",\"explanation\":\"Incorrect; KIR3DL3 is highly polymorphic with 232 alleles. The pseudogenes with limited functional alleles are KIR2DP1 (114 alleles, no proteins) and KIR3DP1 (108 alleles). This misstates which genes lack allelic diversity.\",\"fixedText\":\"Correct to: All KIR genes have multiple alleles, though pseudogenes KIR2DP1 and KIR3DP1 encode no functional proteins and have fewer distinct variants.\",\"evidenceSource\":\"[] (https://www.ebi.ac.uk/ipd/kir/about/statistics/); [](https://onlinelibrary.wiley.com/doi/10.1111/tan.15307)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"A study of the genotypes of 989 individuals representing eight distinct populations found 111 distinct KIR genotypes. [...] [10]\\\"\",\"explanation\":\"Reference [10] is Ljunggren \u0026 KÃ¤rre (1990) on \\\"missing self\\\" hypothesis, which does not discuss KIR genotypes or the study described. No matching study found in searches, indicating unsupported claim or wrong citation.\",\"fixedText\":\"Remove or replace with a verifiable recent study on KIR genotype diversity across populations, e.g., note that studies show hundreds of genotypes with low sharing rates.\",\"evidenceSource\":\"[10] (as provided, unrelated to KIR genotyping)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"30 distinct haplotypes have been classified\\\"\",\"explanation\":\"Outdated from 2005 reference [23]; current literature indicates over 50 haplotypes, with studies identifying hundreds of distinct genotypes and haplotype combinations due to increased sequencing.\",\"fixedText\":\"Update to: Over 50 distinct haplotypes have been described, with extensive variation in gene content and alleles.\",\"evidenceSource\":\"[23]; [](https://pubmed.ncbi.nlm.nih.gov/22948769/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire section lacks recent data]\",\"explanation\":\"The section relies on data from 2002-2005; missing current (as of 2025) updates on KIR diversity from IPD-KIR, including total alleles, per-gene counts, and recent studies on global genotype frequencies, which show even greater diversity.\",\"fixedText\":\"Add updated statistics and cite IPD-KIR for allelic diversity; include brief note on recent findings in haplotype diversity.\",\"evidenceSource\":\"[] (https://www.ebi.ac.uk/ipd/kir/about/statistics/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Genotypes that are inhibitory KIR receptor dominant are likely susceptible to infection and reproductive disorders but protective against [autoimmune diseases](Autoimmune_disease \\\"Autoimmune disease\\\"), whereas activating KIR receptor dominant genotypes are likely susceptible to autoimmunity but protective against viral infection and cancer.[20][23]\",\"explanation\":\"References [20] is a nomenclature proposal with no discussion of disease associations. Reference [23] mentions general links between KIR differences and disease susceptibility but provides no specific details on inhibitory vs. activating dominance and the listed disease risks/protections.\",\"fixedText\":\"Remove citations [20][23] from this claim. Rephrase to a general statement supported by broader literature or cite appropriate sources if adding specifics.\",\"evidenceSource\":\"[20] Andre et al. (2001); [23] Parham (2005)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"The relationship between inhibitory vs stimulatory KIR genotype dominance, however, is more complicated than this because diseases are so diverse and have so many different causes, and immune activation or de-activation may not be protective or harmful at every stage of disease.[20]\",\"explanation\":\"Reference [20] does not discuss disease complexity or stages; it is solely about nomenclature.\",\"fixedText\":\"Remove citation [20].\",\"evidenceSource\":\"[20] Andre et al. (2001)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"KIR2DS2 or 2DS1, which are activating receptors, are strongly correlated with most autoimmune diseases, which is logical because activating receptors induce signaling pathways that lead to cytolysis of target cells.[20][23]\",\"explanation\":\"References [20] and [23] do not support correlations with autoimmune diseases. Literature shows associations with specific autoimmune conditions (e.g., psoriatic arthritis, type 1 diabetes) but not \\\"most\\\" autoimmune diseases, making the claim overstated and unsupported.\",\"fixedText\":\"Remove citations [20][23]. Rephrase to reflect specific, verified associations or generalize without \\\"most\\\" and \\\"strongly correlated.\\\"\",\"evidenceSource\":\"[20] Andre et al. (2001); [23] Parham (2005); Additional evidence from PubMed searches indicating limited, specific associations\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Another activating receptor, KIR3DS1, is protective to hepatitis-C virus infection, is associated with slowing down of [AIDs](HIV/AIDS \\\"HIV/AIDS\\\") progression, and is associated with [cervical cancer](Cervical_cancer \\\"Cervical cancer\\\"), which is associated with a distinct strain of [HPV](Human_papillomavirus \\\"Human papillomavirus\\\").[20][23]\",\"explanation\":\"References [20] and [23] do not discuss KIR3DS1 and these diseases. While protective roles in HCV and HIV are supported in other literature, cervical cancer associations are mixed (some studies show increased frequency in cases, others protective), and no mention of specific HPV strain link in cited refs.\",\"fixedText\":\"Remove citations [20][23]. Correct \\\"AIDs\\\" to \\\"AIDS.\\\" Qualify cervical cancer association as per mixed evidence or remove if not strongly supported.\",\"evidenceSource\":\"[20] Andre et al. (2001); [23] Parham (2005)\"},{\"criticality\":\"Critical\",\"issueType\":\"Original Research / Speculation\",\"problematicText\":\"It is likely that KIR3DS1 is associated with cervical cancer despite its stimulatory nature because cervical tumors generally associate with localized inflammation.[20]\",\"explanation\":\"This is speculative (\\\"It is likely that...\\\") and not verifiable from cited source, which does not discuss this. Wikipedia prohibits original research; such causal explanations require sourced evidence.\",\"fixedText\":\"Remove the speculative sentence and citation.\",\"evidenceSource\":\"[20] Andre et al. (2001)\"},{\"criticality\":\"Critical\",\"issueType\":\"Typographical Error\",\"problematicText\":\"[AIDs](HIV/AIDS \\\"HIV/AIDS\\\")\",\"explanation\":\"Typo: \\\"AIDs\\\" should be \\\"AIDS\\\" (Acquired Immune Deficiency Syndrome).\",\"fixedText\":\"Correct to \\\"AIDS.\\\"\",\"evidenceSource\":\"Standard medical terminology\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire section lacks recent updates]\",\"explanation\":\"The section relies on outdated or mismatched citations (2001, 2005); misses post-2010 developments, such as detailed studies on KIR-HLA interactions in specific diseases (e.g., KIR3DS1/HLA-Bw4 in HIV control, activating KIRs in autoimmunity risks up to 2023 studies).\",\"fixedText\":\"Add sourced summary of key recent associations to fill knowledge gap, ensuring neutrality.\",\"evidenceSource\":\"Recent PubMed reviews (e.g., DOI:10.3389/fimmu.2012.00326 for KIR3DS1 roles)\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"binds to KIR2DL1/2L3\",\"explanation\":\"The antibody 1-7F9 (and lirilumab) binds to three inhibitory KIRs: KIR2DL1, KIR2DL2, and KIR2DL3. Omitting KIR2DL2 inaccurately describes the binding specificity, which is essential for understanding its mechanism in blocking NK cell inhibition.\",\"fixedText\":\"Revise to \\\"binds to KIR2DL1, KIR2DL2, and KIR2DL3\\\"\",\"evidenceSource\":\"[25]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Very similar Lirilumab is intended for the treatment of cancers e.g. leukemia.\",\"explanation\":\"The description lacks update on clinical development status. As of 2025, lirilumab remains investigational, with ongoing phase 1/2 trials for cancers including leukemia and solid tumors, often in combinations; no approval has been granted, making the phrasing outdated without context.\",\"fixedText\":\"Update to reflect current investigational status and add recent citation.\",\"evidenceSource\":\"[](https://immuno-oncologynews.com/lirilumab-iph2102bms-986015/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; entire section\",\"explanation\":\"The section omits key details on clinical progress, such as ongoing trials in combination with PD-1 inhibitors like nivolumab for AML, multiple myeloma, and solid tumors, and relation between 1-7F9/IPH2101 and lirilumab/IPH2102 as closely related antibodies from the same lineage.\",\"fixedText\":\"Add summary of development status and clarify relation between antibodies.\",\"evidenceSource\":\"[](https://clinicaltrials.gov/study/NCT03661320)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"The entire \\\"**KIRs in Cancer Immunotherapies**\\\" subsection, starting from \\\"KIR-targeted therapies are a continuously evolving field...\\\"\",\"explanation\":\"This content discusses KIR blockade with antibodies (e.g., Lirilumab) and direct engineering of NK cells, which are distinct from incorporating KIRs into CAR T cells. The section title specifies \\\"Use of KIRs in CAR T Cell Therapy,\\\" so this material misapplies broader KIR-targeted approaches, potentially duplicating content better suited for the \\\"As a drug target\\\" section per the article structure.\",\"fixedText\":\"Remove the entire \\\"**KIRs in Cancer Immunotherapies**\\\" subsection to maintain section scope; relocate relevant content (e.g., Lirilumab) to \\\"As a drug target\\\" if appropriate elsewhere in the article.\",\"evidenceSource\":\"Article structure: separate sections for \\\"As a drug target\\\" and \\\"Use of KIRs in CAR T Cell Therapy\\\"; refs 25-27 cover Lirilumab as a drug target.\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"Natural Killer cells can be released to kill tumor cells and block the inhibitory KIRs that would invade the immune response.\\\"\",\"explanation\":\"Inhibitory KIRs on NK cells recognize HLA class I and deliver inhibitory signals to prevent NK activation against healthy cells; they do not \\\"invade\\\" the immune response. This inaccurately describes the regulatory mechanism of KIRs in NK function.\",\"fixedText\":\"Since this sentence is part of the off-scope subsection being removed, no additional fix needed here; ensure any retained content accurately describes KIR function in CAR T context.\",\"evidenceSource\":\"Refs [5], [11], [12]: KIRs inhibit NK cytotoxicity upon HLA binding.\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"The Lirilumab has been tested alongside other checkpoint inhibitors like nivolumab which is anti-PD-1 in patients with solid tumors and the results have come out mixed but are suggesting that dual checkpoint blockade could improve efficiency over monotherapies.\\\"\",\"explanation\":\"This claim lacks citations and inaccurately characterizes phase 1 trial results for the lirilumab-nivolumab combination in advanced solid tumors, which showed encouraging safety and objective response rates (e.g., 24% ORR in head and neck cancer subset) without evidence of \\\"mixed\\\" outcomes in that context; later trials in other indications (e.g., AML) failed, but the specific claim misrepresents the solid tumor data.\",\"fixedText\":\"Remove this unsupported and inaccurate claim as part of the off-scope subsection.\",\"evidenceSource\":\"Phase 1 trial data: [](https://news.bms.com/news/details/2016/Interim-Phase-12-Data-Show-Encouraging-Clinical-Benefit-for-Lirilumab-in-Combination-With-Opdivo-nivolumab-in-Patients-With-Advanced-Platinum-Refractory-Squamous-Cell-Carcinoma-of-the-Head-and-Neck/default.aspx); EffiKIR AML trial termination: [](https://www.biopharmadive.com/news/innate-bristol-myers-lirilumab-trial-failure/435552/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"N/A\",\"explanation\":\"The section references ongoing research up to 2022 but lacks updates on KIR-CAR trial progress as of 2025, such as the status of the SynKIR-110 phase 1 trial (STAR-101), which is recruiting and has initiated cohort 2 enrollment in 2025 for mesothelin-expressing solid tumors.\",\"fixedText\":\"Add a sentence summarizing the current trial status: \\\"As of 2025, the phase 1 STAR-101 trial evaluating SynKIR-110 in patients with mesothelin-expressing solid tumors is ongoing, with cohort 2 enrollment initiated this year.\\\" Cite with [](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS5630).\",\"evidenceSource\":\"[](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS5630); [](https://clinicaltrials.gov/study/NCT05568680)\"}],\"slug\":\"Killer-cell_immunoglobulin-like_receptor\",\"title\":\"Killer-cell immunoglobulin-like receptor\",\"content\":\"$1f\",\"description\":\"Killer-cell immunoglobulin-like receptor\\n\\n| Identifiers | |\\n|-------------|-|\\n| Symbol | KIR |\\n| Membranome | 18 |\\n\\nKiller-cell immunoglobulin-like receptors (KIRs), are a family of type I...\",\"metadata\":{\"categories\":[\"KIR\"],\"lastModified\":\"1761586123\",\"contentLength\":\"26140\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"10702\",\"recentViews\":\"10702\",\"dailyAvgViews\":356.73333740234375,\"qualityScore\":1,\"lastViewed\":\"1761882489\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761882490363,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Killer-cell_immunoglobulin-like_receptor\"],\"queryHash\":\"[\\\"page\\\",\\\"Killer-cell_immunoglobulin-like_receptor\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Killer-cell immunoglobulin-like receptor\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of natural killer (NK) cells and a minority of T cells.[1][2] In humans, they are encoded in the leukocyte receptor complex (LRC) on chromosome 19q13.4; the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.[3][4] NK cells use KIRs to detect perturbations or absence of self-HLA class...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"KIR\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Killer-cell_immunoglobulin-like_receptor\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Killer-cell immunoglobulin-like receptor\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of natural killer (NK) cells and a minority of T cells.[1][2] In humans, they are encoded in the leukocyte receptor complex (LRC) on chromosome 19q13.4; the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.[3][4] NK cells use KIRs to detect perturbations or absence of self-HLA class...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Killer-cell_immunoglobulin-like_receptor\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Killer-cell immunoglobulin-like receptor\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:46.123Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Killer-cell immunoglobulin-like receptor\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of natural killer (NK) cells and a minority of T cells.[1][2] In humans, they are encoded in the leukocyte receptor complex (LRC) on chromosome 19q13.4; the KIR region is approximately 150 kilobases and contains 16 genes, including 14 loci encoding functional proteins and 2 pseudogenes.[3][4] NK cells use KIRs to detect perturbations or absence of self-HLA class...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="MGNmM2JmMWUtM2JhMi00Mzk2LTkxODItMTVhMDIwMDZiNTMz">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Killer-cell_immunoglobulin-like_receptor\"}]}]\n"])</script></body></html>